10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2018

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________to _____________

Commission File Number: 001-37357

INNOVATION PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Nevada	30-0565645
(State or other jurisdiction of	(I.R.S. Empl. Ident. No.)
incorporation or organization)

100 Cummings Center, Suite 151-B

Beverly, MA 01915

(Address of principal executive offices, Zip Code)

(978)-921-4125

(Registrant’s telephone number, including area code)

_________________________________________________________

(Former Name, Former Address and Former Fiscal Year if Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer	¨	Accelerated Filer	x
Non-Accelerated Filer	¨	Smaller reporting company	¨
(Do not check if a smaller reporting company)		Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares outstanding of each of the issuer’s classes of common equity, as of May 6, 2018 is as follows:

Class of Securities	Shares Outstanding
Common Stock Class A, $0.0001 par value	155,091,427
Common Stock Class B, $0.0001 par value	None

INNOVATION PHARMACEUTICALS INC.

FORM 10-Q

For the Quarter Ended March 31, 2018

TABLE OF CONTENTS

Item 1.	Financial Statements	4
	Condensed Balance Sheets as of March 31, 2018 (unaudited) and June 30, 2017 (audited)	4
	Condensed Statements of Operations (unaudited) for the three months and nine months ended March 31, 2018 and 2017	5
	Condensed Statements of Cash Flows (unaudited) for the nine months ended March 31, 2018 and 2017	6
	Notes to Condensed Financial Statements (unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	32
Item 4.	Controls and Procedures	32

Item 1.	Legal Proceedings	33
Item 1A	Risk Factors	33
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	33
Item 3.	Defaults Upon Senior Securities	33
Item 4.	Mine Safety Disclosures	33
Item 5.	Other Information	33
Item 6.	Exhibits	33
SIGNATURES		35

2

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning our future drug development plans and projected timelines for the initiation and completion of preclinical and clinical trials; the potential for the results of ongoing preclinical or clinical trials; other statements regarding our future product development and regulatory strategies, including with respect to specific indications; any statements regarding our future financial performance, results of operations, expenditures or sufficiency of capital resources to fund our operating requirements; and any other statements which are other than statements of historical fact. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research and development efforts and to create effective, commercially-viable drugs; our ability to effectively and timely conduct clinical trials; our ability to ultimately distribute our drug candidates; compliance with regulatory requirements; and our capital needs, as well as other factors described elsewhere in this report and our other reports filed with the Securities and Exchange Commission (the “SEC”). Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Forward-looking statements speak only as of the date on which they are made. Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this report as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the SEC that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business. Readers are cautioned not to put undue reliance on forward-looking statements.

For further information about these and other risks, uncertainties and factors, please review the disclosure included in our Annual Report on Form 10-K under “Part I, Item 1A, Risk Factors” and in this report under “Part II, Item 1A, Risk Factors.”

3

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

INNOVATION PHARMACEUTICALS INC.

CONDENSED BALANCE SHEETS

(Rounded to nearest thousand except for shares data)

	March 31,			June 30,
	2018			2017
	(Unaudited)
ASSETS
Current Assets:
Cash	$	1,336,000		$	4,141,000
Prepaid expenses		40,000			308,000
Security deposits		78,000			-
Subscription receivable		-			26,000
Total Current Assets		1,454,000			4,475,000
Other Assets:
Patents - net		4,032,000			4,212,000
Equipment - net		93,000			120,000
Deferred offering costs - net		173,000			227,000
Security deposits		-			78,000
Total Other Assets		4,298,000			4,637,000
Total Assets	$	5,752,000		$	9,112,000
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
Current Liabilities:
Accounts payable - (including related party payables of approximately $1,486,000 and 1,506,000, respectively)	$	4,122,000		$	4,699,000
Accrued expenses - (including related party accruals of approximately $25,000 and $38,000, respectively)		306,000			711,000
Accrued salaries and payroll taxes - (including related party accrued salaries of approximately $2,953,000 and $2,953,000, respectively)		3,017,000			3,144,000
Convertible note payable - related party		2,022,000			2,022,000
Total Current Liabilities		9,467,000			10,576,000
Total Liabilities		9,467,000			10,576,000
Commitments and contingencies (Note 7)
Stockholders’ Deficiency
Preferred stock, $0.001 par value, 10,000,000 designated shares, no shares issued and outstanding		-			-
Common Stock - Class A, $0.0001 par value, 300,000,000 shares authorized, 147,091,427 and 135,536,501 issued as of March 31, 2018 and June 30, 2017, respectively, 147,091,427 and 135,274,421 outstanding as of March 31, 2018 and June 30, 2017, respectively		15,000			14,000
Common Stock - Class B, (10 votes per share); $0.0001 par value, 100,000,000 shares authorized, no shares issued and outstanding as of March 31, 2018 and June 30, 2017, respectively		-			-
Additional paid-in capital		77,324,000			68,295,000
Accumulated deficit		(81,054,000	)		(69,553,000	)
Treasury Stock, at cost (0 shares and 262,080 shares as of March 31, 2018 and June 30, 2017, respectively)		-			(220,000	)
Total Stockholders’ Deficiency		(3,715,000	)		(1,464,000	)
Total Liabilities and Stockholders’ Deficiency	$	5,752,000		$	9,112,000

The accompanying notes are an integral part of these condensed financial statements

4

INNOVATION PHARMACEUTICALS INC.

CONDENSED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS AND NINE MONTHS ENDED MARCH 31, 2018 AND 2017

(Unaudited)

(Rounded to nearest thousand except for shares and per share data)

	For the Three Months Ended						For the Nine Months Ended
	March 31,						March 31,
	2018			2017			2018			2017
Revenues	$	-		$	-		$	-		$	-
Operating expenses:
Research and development expenses		1,776,000			3,182,000			9,544,000			8,142,000
General and administrative expenses		295,000			331,000			889,000			1,037,000
Officers' payroll and payroll tax expenses		132,000			138,000			392,000			398,000
Professional fees		195,000			201,000			525,000			562,000
Total operating expenses		2,398,000			3,852,000			11,350,000			10,139,000
Loss from operations		(2,398,000	)		(3,852,000	)		(11,350,000	)		(10,139,000	)
Other income (expenses)
Interest income		-			-			1,000			2,000
Interest expense		(51,000	)		(51,000	)		(152,000	)		(152,000	)
Total other income - net		(51,000	)		(51,000	)		(151,000	)		(150,000	)
Loss before provision for income taxes		(2,449,000	)		(3,903,000	)		(11,501,000	)		(10,289,000	)
Provision for income taxes		-			-			-			-
Net loss	$	(2,449,000	)	$	(3,903,000	)	$	(11,501,000	)	$	(10,289,000	)
Basic and diluted loss per share	$	(0.02	)	$	(0.03	)	$	(0.08	)	$	(0.08	)
Weighted average number of common shares outstanding		146,071,627			127,270,598			141,296,395			125,599,470

The accompanying notes are an integral part of these condensed financial statements.

5

INNOVATION PHARMACEUTICALS INC.

CONDENSED STATEMENTS OF CASH FLOW

FOR THE NINE MONTHS ENDED MARCH 31, 2018 AND 2017

(Unaudited)

(Rounded to nearest thousand)

	2018			2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(11,501,000	)	$	(10,289,000	)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock and stock options issued as payment for compensation, services rendered and financing costs		1,665,000			1,026,000
Amortization of patent costs		289,000			277,000
Depreciation of equipment		28,000			24,000
Changes in operating assets and liabilities:
Prepaid expenses and security deposits		268,000			165,000
Accounts payable		(578,000	)		664,000
Accrued expenses		(406,000	)		130,000
Accrued officers' salaries and payroll taxes		(127,000	)		54,000
Net cash used in operating activities		(10,362,000	)		(7,949,000	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property, plant and equipment		-			(63,000	)
Patent costs		(108,000	)		(256,000	)
Net cash used in investing activities		(108,000	)		(319,000	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Sales of common stock, net of offering costs		7,837,000			7,571,000
Purchase of treasury stock		(172,000	)		-
Net cash provided by financing activities		7,665,000			7,571,000
NET DECREASE IN CASH		(2,805,000	)		(697,000	)
CASH, BEGINNING OF PERIOD		4,141,000			6,310,000
CASH, END OF PERIOD	$	1,336,000		$	5,613,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest	$	156,000		$	44,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH FLOW
INVESTING AND FINANCING ACTIVITIES
Commitment shares issued as deferred offering costs	$	215,000		$	-
Reversal of subscription receivable to treasury stock	$	26,000		$	-

The accompanying notes are an integral part of these condensed financial statements.

6

INNOVATION PHARMACEUTICALS INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

MARCH 31, 2018

 (Unaudited)

Note 1. Basis of Presentation and Nature of Operations

Unaudited Interim Financial Information

The accompanying unaudited condensed financial statements of Innovation Pharmaceuticals Inc. have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or the SEC, including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements for the year ended June 30, 2017, included in our Annual Report on Form 10-K for the year ended June 30, 2017.

In the opinion of the management of Innovation Pharmaceuticals Inc., all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three-month and nine-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. When used in these notes, the terms “Company”, “we”, “us” or “our” mean Innovation Pharmaceuticals Inc.

Basis of Presentation and Name Change

Innovation Pharmaceuticals Inc. (the “Company”) was incorporated on August 1, 2005 in the State of Nevada. Effective June 5, 2017, the Company amended its Articles of Incorporation and changed its name from Cellceutix Corporation to Innovation Pharmaceuticals Inc. In accordance with Section 92A.180 of the Nevada Revised Statutes, stockholder approval of the name change was not required.

The Company is a clinical stage biopharmaceutical company and has no customers, products or revenues to date. The Company’s common stock is quoted on OTCQB, symbol “IPIX”.

Nature of Operations - Overview

We are in the business of developing innovative small molecule therapies to treat diseases with significant medical need, particularly in the areas of inflammatory diseases, cancer, dermatology and anti-infectives. Our strategy is to use our business and scientific expertise to maximize the value of our pipeline. We will do this by focusing initially on our lead compounds, Brilacidin, Kevetrin and Prurisol and advancing them as quickly as possible along the regulatory pathway. We will develop the highest quality data and broadest intellectual property to support our compounds.

We currently own all development and marketing rights to our products. In order to successfully develop and market our products, we may have to partner with other companies. Prospective partners may require that we grant them significant development and/or commercialization rights in return for agreeing to share the risk of development and/or commercialization.

Note 2. Going Concern and Liquidity

As of June 30, 2017, the Company adopted Accounting Standards Codification 205-40. This guidance amended the existing requirements for disclosing information about an entity’s ability to continue as a going concern and explicitly requires management to assess an entity’s ability to continue as a going concern and to provide related disclosure in certain circumstances. This guidance was effective for annual reporting periods ending after December 15, 2016, and for annual and interim reporting periods thereafter. The following information reflects the results of management’s assessment, plans and conclusion of the Company’s ability to continue as a going concern.

7

We have incurred recurring losses since inception and expect to continue to incur losses as a result of costs and expenses related to our research and continued development of our compounds and our corporate general and administrative expenses. As of March 31, 2018, the Company has an accumulated deficit of approximately $81.1 million, representative of recurring losses since inception. The Company is a development stage pharmaceutical company that has no sales as it does not have any products in the market and will continue to not have any revenues until it begins to market its products after it has obtained the necessary Federal Drug Administration (the “FDA”) approval. As a result, the Company expects to continue to incur losses over the next 12 months from the date of this filing.

At March 31, 2018, the Company’s cash amounted to $1.3 million and current liabilities amounted to $9.5 million, of which $6.5 million were payables to related parties with no immediate payment terms (See Note 8- Related Party Transactions in the Notes to Condensed Financial Statements section below). The Company had expended substantial funds on its clinical trials and expects to continue our spending on research and development expenditures. The Company’s net cash used in operating activities for the nine months ended March 31, 2018 was approximately $10.4 million, and current projections indicate that the Company will have continued negative cash flows from operating activities for the foreseeable future. Our net losses incurred for the nine months ended March 31, 2018 and 2017, amounted to $11.5 million and $10.3 million, respectively, and we had a working capital deficit of approximately $8.0 million and $6.1 million, respectively at March 31, 2018 and June 30, 2017.

Accordingly, the Company’s planned operations, including total budgeted expenditures of approximately $12.2 million for the next twelve months, raise doubt about its ability to continue as a going concern. The Company’s plans to alleviate the doubt of its ability to continue as a going concern primarily include controlling the timing and spending on its research and development programs, thereby being able to decrease its current budgeted expenditures mentioned above for the next 12 months, as needed and to continue raising additional funds through equity financings from its common stock purchase agreement with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”). The Company may consider other plans to fund operations including: (1) raising additional capital through debt financings or from other sources; (2) additional funding through new relationships to help fund future clinical trial costs (i.e. licensing and partnerships); (3) reducing spending on one or more research and development programs by discontinuing development; and/or (4) restructuring operations to change its overhead structure. The Company may issue securities, including shares of common stock, shares of preferred stock and stock purchase contracts through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-3 filed with the SEC on September 11, 2017 and declared effective on September 21, 2017. Pursuant to the instructions to Form S-3, if the Company’s non-affiliate market capitalization as of an applicable measurement time, such as upon the filing of the Company’s Annual Report on Form 10-K, does not equal or exceed $75 million, the Company will be unable to offer and sell securities from its effective shelf registration statement on Form S-3.

The Company’s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.

The Company believes that the actions discussed above are probable of occurring and alleviating the substantial doubt raised by our historical operating results and satisfying our estimated liquidity needs twelve months from the issuance of the accompanying financial statements.

On September 6, 2017, the Company entered into a new $30 million common stock purchase agreement with Aspire Capital (the “2017 Agreement”) to replace the prior 2015 $30 million common stock purchase agreement with Aspire Capital (the “2015 Agreement”). During the period from July 1, 2017 to September 5, 2017, the Company generated proceeds of approximately $2.1 million under the 2015 Agreement from the sale of approximately 2.6 million shares of its common stock. During the period from September 6, 2017 to March 31, 2018, the Company generated proceeds of approximately $5.7 million under the 2017 Agreement from the sale of approximately 8.7 million shares of its common stock. As of March 31, 2018, the available balance under the 2017 Agreement is approximately $24.3 million.

8

Note 3. Significant Accounting Policies and Recent Accounting Pronouncements

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research accruals, recoverability of long-lived assets, measurement of stock-based compensation, and the periods of performance under collaborative research and development agreements. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.

Net Loss Per Share

Basic and diluted loss per share is computed based on the weighted-average common shares and common share equivalents outstanding during the period. Common share equivalents consist of stock options, convertible notes payable underlying shares and unvested restricted stock. Common share equivalents of 47 million and 46 million shares of common stock were excluded from the computation of diluted loss per share for the nine months ended March 31, 2018 and 2017, respectively, because we incurred net losses for the nine months ended March 31, 2018 and 2017, and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive and are therefore not included in the calculations.

Treasury Stock

The Company accounts for treasury stock using the cost method. There were 0 shares and 262,080 shares of treasury stock outstanding, purchased at a total cumulative cost of $0 and $220,000 at March 31, 2018 and June 30, 2017, respectively (see Note 10).

Treasury stock, representing shares of the Company’s common stock that have been acquired for payroll tax withholding on vested stock grants, is recorded at its acquisition cost and these shares are not considered outstanding.

Accounting for Stock Based Compensation

The stock-based compensation expense incurred by the Company for employees and directors in connection with its stock option plan is based on the employee model of ASC 718, and the fair market value of the options is measured at the grant date. Under ASC 718, an employee is defined as “An individual over whom the grantor of a share-based compensation award exercises or has the right to exercise sufficient control to establish an employer-employee relationship based on common law as illustrated in case law and currently under U.S. tax regulations”. Our consultants do not meet the employer-employee relationship as defined by the IRS and therefore are accounted for under ASC 505-50.

ASC 505-50-30-11 further provides that an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date:

i.	The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and
ii.	The date at which the counterparty’s performance is complete.

We have elected to use the Black-Scholes-Merton pricing model to determine the fair value of stock options on the dates of grant. Restricted stock is measured based on the fair market values of the underlying stock on the dates of grant. We recognize stock-based compensation using the straight-line vesting method over the requisite service period of the equity awards.

9

The components of stock-based compensation expense included in the Company’s Condensed Statements of Operations for the three months and nine months ended March 31, 2018 and 2017 are as follows (rounded to nearest thousand):

	Three months ended March 31				Nine months ended March 31
	2018		2017		2018		2017
Research and development expenses
Professional fees	$	80,000	$	5,000	$	80,000	$	55,000
Employees’ bonus		41,000		48,000		115,000		110,000
Officers’ bonus		144,000		283,000		1,470,000		861,000
Total stock-based compensation expense	$	265,000	$	336,000	$	1,665,000	$	1,026,000

Recent Adopted Accounting Pronouncements

Stock Compensation - In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which simplified the income tax consequences, accounting for forfeitures and classification on the Statement of Cash Flows with (i) excess tax benefits being classified as cash inflows provided by operating activities, and (ii) cash paid to taxing authorities arising from the withholding of shares from employees being classified as cash outflows used in financing activities. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016, with early adoption permitted. This new pronouncement was adopted on July 1, 2016 and did not have a material effect on the Company’s financial position or results of operations, but had an effect of the classification of cash paid to taxing authorities arising from the withholding of shares from employees (treasury stock), classified as cash outflows used in financing activities.

In June 2014, the FASB issued ASU 2014-12, “Compensation—Stock Compensation.” The amendments in this ASU apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target can be achieved after the requisite service period. This ASU is the final version of Proposed ASU EITF-13D, “Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period,” which has been deleted. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. As indicated in the definition of vest, the stated vesting period (which includes the period in which the performance target could be achieved) may differ from the requisite service period. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The implementation of this standard did not have a material impact on the Company’s accompanying condensed financial statements.

Recently Issued Accounting Guidance

In May 2014, the FASB issued authoritative guidance that defines how companies should report revenues from contracts with customers. The standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It provides companies with a five-step, principles-based model to use in accounting for revenue and supersedes current revenue recognition requirements, including most industry-specific and transaction-specific revenue guidance. In August 2015, the FASB deferred the effective date of the new revenue standard by one year. As a result, the new standard would not be effective for the Company until 2019. In addition, the FASB is allowing companies to early adopt this guidance for non-public entities beginning in fiscal year 2017. The guidance permits an entity to apply the standard retrospectively to all prior periods presented, with certain practical expedients, or apply the requirements in the year of adoption, through a cumulative adjustment. The Company will apply this new guidance when it becomes effective and has not yet selected a transition method. The Company, due to not having any revenue currently and in the foreseeable future, has concluded that the impact of the adoption of this accounting standard on its financial statements will not be material.

10

In February 2016, FASB issued ASU No. 2016-02, “Leases (Topic 842)”. The guidance requires that a lessee recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right of use asset representing its right to use the underlying asset for the lease term. The guidance requires the following for finance leases: the right-of-use asset and a lease liability will be initially measured at the present value of the lease payments, in the statement of financial position; interest on the lease liability will be recognized separately from amortization of the right-of-use asset in the statement of comprehensive income; and repayments of the principal portion of the lease liability will be classified within financing activities and payments of interest on the lease liability and variable lease payments within operating activities in the statement of cash flows. The guidance requires the following for operating leases: the right-of-use asset and a lease liability will be initially measured at the present value of the lease payments, in the statement of financial position; a single lease cost will be recognized, calculated so that the cost of the lease is allocated over the lease term on a generally straight-line basis; and all cash payments will be classified within operating activities in the statement of cash flows. Under Topic 842 the accounting applied by a lessor is largely unchanged from that applied under previous U.S. GAAP. The amendments in Topic 842 are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Management has determined that based on current accounting and lease contract information the adoption of ASU No. 2016-02 is not expected to have a significant impact on the Company’s financial position, results of operations and disclosures. However, management is continually evaluating the future impact of ASU No. 2016-02 based on changes in the Company’s financial statements through the period of adoption.

Intangibles, Goodwill and Other —In January 2017, the FASB issued ASU No. 2017-04, “Intangibles – Goodwill and Other (Topic 350) – Simplifying the Test for Goodwill Impairment” (“ASU No. 2017-04”). To simplify the subsequent measurement of goodwill, ASU No. 2017-04 eliminates Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, ASU No. 2017-04 requires an entity to perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. ASU No. 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore, the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU No. 2017-04 is effective for fiscal years beginning after December 15, 2019. The Company will adopt ASU No. 2017-04 commencing in the first quarter of fiscal 2021. The Company does not believe this standard will have a material impact on its financial statements or the related footnote disclosures.

Statement of Cash Flows — In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force)” (“ASU No. 2016-15”). ASU No. 2016-15 clarifies how certain cash receipts and payments should be presented in the statement of cash flows. ASU No. 2016-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company will adopt ASU No. 2016-15 commencing in the first quarter of fiscal 2019. The Company does not believe this standard will have a material impact on its financial statements or the related footnote disclosures.

Note 4. Patents, net

Patents, net consisted of the following (rounded to nearest thousand):

	Useful life	March 31,			June 30,
	(years)	2018			2017
Purchased Patent Rights – Brilacidin, and related compounds	14	$	4,082,000		$	4,082,000
Purchased Patent Rights – Anti-microbial – surfactants and related compounds	12		144,000			144,000
Patents – Kevetrin and related compounds	17		1,417,000			1,308,000
			5,643,000			5,534,000
Less: Accumulated amortization for Brilacidin, Anti-microbial- surfactants and related compounds			(1,386,000	)		(1,158,000	)
Accumulated amortization for Patents –Kevetrin and related compounds			(225,000	)		(164,000	)
		$	4,032,000		$	4,212,000

11

The patents are amortized on a straight-line basis over the useful lives of the assets, determined to be 12-17 years from the date of acquisition.

Amortization expense was approximately $96,000 and $95,000, for the three months ended March 31, 2018 and 2017, respectively and was approximately $289,000, and $277,000 for the nine months ended March 31, 2018 and 2017, respectively.

At March 31, 2018, the future amortization period for all patents was approximately 7.43 years to 16.75 years. Future estimated annual amortization expenses are approximately $96,000 for the year ending June 30, 2018, $383,000 for each year from 2019 to 2025, $374,000 for the year ending June 30, 2026, $371,000 for the year ending June 30, 2027, $134,000 for the year ending June 30, 2028, $80,000 for the years ending June 30, 2029 through the years ended 2032, $41,000 for the year ending June 30, 2033, $10,000 for the year ending June 30, 2034 and $2,000 for the year ending June 30, 2035.

Compounds with Activity Against Gram-Negative Bacteria and Fungi

As research at the Company is now focused on supporting its clinical trials, we have reduced costs associated with the licensing of intellectual property for gram-negative bacteria and anti-fungal compounds by returning our patent portfolio titled “Compounds and Methods for Treating Candidiasis and Aspergillus Infections” back to the university co-licensor. The Company at this time does not have any active gram-negative or anti-fungal programs and therefore has decided not to pay for the maintenance of these Patent Rights. The net book value of the impaired patent as of March 31, 2018 is not material.

Note 5. Accrued Expenses

Accrued expenses consisted of the following (rounded to nearest thousand):

	March 31,		June 30,
	2018		2017
Accrued research and development consulting fees	$	281,000	$	673,000
Accrued rent (Note 8) – related parties		13,000		21,000
Accrued interest – (Note 9) related parties		12,000		17,000
Total	$	306,000	$	711,000

Note 6. Accrued Salaries and Payroll Taxes – Related Parties and Other

Accrued salaries and payroll taxes consisted of the following (rounded to nearest thousand):

	March 31,		June 30,
	2018		2017
Accrued salaries - related parties	$	2,823,000	$	2,823,000
Accrued payroll taxes - related parties		130,000		130,000
Accrued employee bonuses		-		86,000
Withholding tax - payroll		64,000		105,000
Total	$	3,017,000	$	3,144,000

12

Note 7. Commitments and Contingencies

Lease Commitments

Operating Leases – Rental Property

The Company signed a lease extension agreement with Cummings Properties which began on October 1, 2013. The lease is for a term of five years ending on September 30, 2018, and requires monthly payments of $18,000. Innovative Medical Research Inc., a company owned by Leo Ehrlich and Dr. Krishna Menon, officers of the Company, has co-signed the lease and subleases 200 square feet of space previously used by the Company and pays the Company $900 per month.

As of March 31, 2018, future minimum lease payments to Cummings Properties required under the non-cancelable operating lease are as follows (rounded to nearest thousand):

Year ending June 30,
2018	$	54,000
2019		54,000
Total minimum payments	$	108,000

Rent expense, net of lease income, under this operating lease agreement was approximately $53,000 and $52,000 for the three months ended March 31, 2018 and 2017, respectively and was approximately $157,000 and $153,000 for the nine months ended March 31, 2018 and 2017, respectively. Before September 2013, the Company paid rent to Kard Scientific for office space and details are shown at Note 8 - Related Party Transactions below.

Operating Leases - Equipment

We leased equipment under a non-cancelable operating lease that expired in April, 2018. As of March 31, 2018, there was no future minimum rental commitment for our operating lease for the next twelve months.

Contractual Commitments

The Company has total contractual minimum commitments of approximately $1.0 million to contract research organizations as of March 31, 2018. Expenses are recognized when services are performed by the contract research organizations.

Note 8. Related Party Transactions

Office Lease

Dr. Menon, the Company’s principal shareholder, President of Research, and Director, also serves as the Chief Operating Officer and Director of Kard Scientific (“KARD”). On December 7, 2007, the Company began renting office space from KARD, and since September 1, 2013, the Company no longer leases space from KARD. At March 31, 2018 and June 30, 2017, rent payable to KARD of approximately $13,000 and $21,000, respectively, were included in accrued expenses.

In September 2013, the Company signed a lease extension agreement with Cummings Properties for the company’s offices and laboratories at 100 Cummings Center, Suite 151-B Beverly, MA 01915. The lease is for a term of five years from October 1, 2013 to September 30, 2018 and requires monthly payments of approximately $18,000. The Company had taken over the space occupied by KARD. In addition, Innovative Medical Research Inc., (“Innovative Medical”) a company owned by Mr. Ehrlich and Dr. Menon, officers of the Company, has co-signed the lease and rents approximately 200 square feet of office space, the space previously used by the Company and pays the Company $900 per month, the same amount the Company previously paid KARD. Innovative Medical paid total rent of approximately $3,000 and $9,000 to the Company for both of the three months and nine months ended March 31, 2018 and 2017 and the rental payment was offset with the accrued rent owed to KARD.

Clinical Studies

The Company previously engaged KARD to conduct specified pre-clinical studies. The Company did not have an exclusive arrangement with KARD. All work performed by KARD needed prior approval by the executive officers of the Company, and the Company retained all intellectual property resulting from the services by KARD. The Company now has its own research study capabilities and no longer uses KARD. At March 31, 2018 and June 30, 2017, the accrued research and development expenses payable to KARD was approximately $1,486,000 and this amount was included in accounts payable.

Other related party transactions are disclosed in Note 9 below.

13

Note 9. Convertible Note Payable - Related Party

During the year ended June 30, 2010, Mr. Ehrlich loaned the Company a total of approximately $973,000. A condition for this note was that the Ehrlich Promissory Note A and Ehrlich Promissory Note B be replaced with a new note, Ehrlich Promissory Note C. The Ehrlich Promissory Note C is an unsecured demand note that bears 9% simple interest per annum and is convertible into the Company’s Class A common stock at $0.50 per share. The note requires that the interest rate on the amounts due on Ehrlich Promissory Notes A and B be changed retroactively, beginning October 1, 2009, to 9%. On April 1, 2011, the Company amended the Ehrlich Promissory Note C and agreed to retroactively convert accrued interest of approximately $97,000 through December 31, 2010 into additional principal. During the year ended June 30, 2011, Mr. Ehrlich loaned the Company an additional (approximate) $997,000 which brought the total balance of the demand note to approximately $2,002,000. During the year ended June 30, 2012, Mr. Ehrlich loaned the Company an additional $20,000 which brought the balance of this demand note to approximately $2,022,000.

On May 8, 2012, the Company did not have the ability to repay the Ehrlich Promissory Note C loan and agreed to change the interest rate on the outstanding balance of principal and interest of approximately $2,248,000, as of March 31, 2012, from 9% simple interest to 10% simple interest, and the Company issued 2,000,000 Equity Incentive Options exercisable at $0.51 per share equal to 110% of the closing bid price of $0.46 per share on May 7, 2012. Options are valid for ten (10) years from the date of issuance.

At March 31, 2018 and June 30, 2017, approximately $12,000 and $17,000, respectively, is the accrued interest payable on this note.

At March 31, 2018 and June 30, 2017, principal balance of this demand note was approximately $2,022,000.

Note 10. Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding

Current Equity Incentive Plan

2016 Equity Incentive Plan

On June 30, 2016, the Board of Directors adopted the Company’s 2016 Equity Incentive Plan (the “2016 Plan”). The 2016 Plan became effective upon adoption by the Board of Directors on June 30, 2016.

Up to 20,000,000 shares of the Company’s Class A common stock may be issued under the 2016 Plan (subject to adjustment as described in the 2016 Plan); provided that (1) no Outside Director (as defined in the 2016 Plan) may be granted awards covering more than 250,000 shares of common stock in any year and (2) no participant shall be granted, during any one year period, options to purchase common stock and stock appreciation rights with respect to more than 4,000,000 shares of common stock in the aggregate or any other awards with respect to more than 2,500,000 shares of common stock in the aggregate. The 2016 Plan permits the grant of ISOs, non-qualified stock options, stock appreciation rights, restricted awards, performance share awards and performance compensation awards to employees, directors, and consultants of the Company and its affiliates.

In connection with adoption of the 2016 Plan, the Board of Directors also approved forms of Incentive Stock Option Agreement for Employees, Non-qualified Stock Option Agreement for Employees, Non-qualified Stock Option Agreement for Non-Employee Directors, Restricted Stock Award Agreement for Employees and Restricted Stock Award Agreement for Non-Employee Directors that will be utilized by the Company to grant options and restricted shares under the 2016 Plan.

14

Stock Options Issued and Outstanding

The following table summarizes all stock option activity under the Company’s equity incentive plans:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding at June 30, 2017		40,655,245		$	0.22		3.61	$	31,662,730
Granted		1,070,826			0.75		8.14
Forfeited/expired		(277,924	)		2.44
Outstanding at March 31, 2018		41,448,147			0.22		3.01	$	14,819,300
Exercisable at March 31, 2018		40,452,299			0.21		2.87	$	14,819,300

The fair value of options granted for the nine months ended March 31, 2018 and 2017 was estimated on the date of grant using the Black Scholes model that uses assumptions noted in the following table.

	Nine months ended
	March 31,
	2018	2017
Expected term (in years)	5 - 10	3 - 10
Expected stock price volatility	52.80% to 106.01%	57.63% to 111.62%
Risk-free interest rate	2.15% to 2.56%	0.71% to 2.49%
Expected dividend yield	0	0

Stock-Based Compensation

The Company recognized approximately $265,000 and $336,000 of total stock-based compensation costs related to stock and stock options awards for the three months ended March 31, 2018 and 2017, respectively. The Company recognized approximately $1,665,000 and $1,026,000 of total stock-based compensation costs related to stock and stock options awards for the nine months ended March 31, 2018 and 2017, respectively.

The $1,665,000 of total stock-based compensation expense for the nine months ended March 31, 2018 included approximately $677,000 of stock options expense and $988,000 of stock awards.

For the nine months ended March 31, 2018

On February 1, 2018, the Company agreed to issue options to purchase 75,000 shares of common stock to each of two consultants for specified services to be provided from February 1, 2018 to January 31, 2019 in accordance with agreements with the consultants. During the nine months ended March 31, 2018, the Company recorded approximately $8,000 of related stock-based compensation.

On February 10, 2017, the Company entered into verbal agreements with two consultants to issue options to purchase 50,000 shares of common stock and 75,000 shares of common stock, respectively, to the two consultants for services to be performed from February 13, 2017 to January 31, 2018 in accordance with their consulting agreements. The Company formally signed the agreements with the two consultants on March 13, 2018. During the nine months ended March 31, 2018, the Company recorded approximately $72,000 of related stock-based compensation.

15

On September 1, 2017, the Company agreed to grant to Dr. Arthur Bertolino, the President and Chief Medical Officer of the Company, under the 2016 Plan (i) 1,066,667 shares of restricted stock and (ii) a ten-year option to purchase 617,839 shares of the Company’s Class A common stock at an exercise price of $0.705 per share. Both shares and options shall vest upon the earliest to occur of the following: (1) 50% upon the first anniversary of the effective date and the remaining 50% upon the second anniversary of the effective date; (2) shares of the Company’s common stock close above $3.00 per share (as may be adjusted for any stock splits or similar actions); (3) the commencement of trading of shares of the Company’s common stock on a national securities exchange; or (4) upon a change in control of the Company. The 1,066,667 shares were valued at approximately $752,000 and the 617,839 stock options valued at approximately $399,000. Both shares and options will be amortized over 2 years to September 1, 2019 unless the probability of the other above vesting requirements occurring are met at an earlier date. At March 31, 2018, the Company determined that it was not probable that these accelerated vesting provisions would occur earlier than the scheduled vesting date. During the three months and nine months ended March 31, 2018, the Company recorded approximately $144,000 and $336,000 of total stock-based compensation, respectively. The $144,000 of stock-based compensation expense for the three months ended March 31, 2018 included approximately $50,000 of stock option expense and $94,000 of stock awards. The $336,000 of stock-based compensation expense for the nine months ended March 31, 2018 included approximately $117,000 of stock option expense and $219,000 of stock awards.

On September 1, 2017, the Company agreed to grant to Ms. Jane Harness, the Senior Vice President, Clinical Sciences and Portfolio Management of the Company under the 2016 Plan (i) 58,394 shares of restricted stock and (ii) a ten-year option to purchase 172,987 shares of the Company’s Class A common stock at an exercise price of $0.705 per share. Both shares and options shall vest upon the earliest to occur of the following: (1) one third upon the first anniversary of the effective date, one third upon the second anniversary of the effective date, and the remaining one third upon the third anniversary of the effective date; or (2) upon a change in control of the Company. The 58,394 shares were valued at approximately $41,000 and the 172,987 stock options valued at approximately $112,000. Both shares and options will be amortized over 3 years to September 1, 2020 unless the other vesting requirements are met sooner. During the three months and nine months ended March 31, 2018, the Company recorded approximately $13,000 and $30,000 of total stock-based compensation, respectively. The $13,000 of stock-based compensation expense for the three months ended March 31, 2018 included approximately $9,000 of stock option expense and $4,000 of stock awards. The $30,000 of stock-based compensation expense for the nine months ended March 31, 2018 included approximately $22,000 of stock option expense and $8,000 of stock awards.

On September 1, 2017, the Company agreed to grant to Anne Ponugoti, under the 2016 Plan, ten-year options to purchase 5,000 shares of the Company’s common stock at an exercise price of $0.705 per share, which shall vest upon the earliest to occur of the following: (1) one third upon the first anniversary of the effective date, one-third upon the second anniversary of the effective date, and the remaining one-third upon the third anniversary of the effective date; or (2) upon a change in control of the Company. The 5,000 stock options were valued at approximately $3,000 and will be amortized over 3 years to September 1, 2020 unless the other vesting requirements are met sooner. During the three months and nine months ended March 31, 2018, the Company recorded approximately $300 and $700 of stock option expense for this option grant.

On January 9, 2017, the Company and Ms. Ponugoti entered into an executive employment agreement as the Company’s Associate Director, Clinical Sciences, effective on February 1, 2017. Pursuant to the employment agreement, the Company issued 10,000 shares of restricted stock and options to purchase 30,000 shares of common stock under the 2016 Plan. During the three months and nine months ended March 31, 2018, the Company recorded approximately $3,000 and $9,000 of total stock-based compensation, respectively. The $3,000 of stock-based compensation expense for the three months ended March 31, 2018 included approximately $2,000 of stock option expense and $1,000 of stock awards. The $10,000 of stock-based compensation expense for the nine months ended March 31, 2018 included approximately $7,000 of stock option expense and $3,000 of stock awards.

Purchase of Treasury Stock - cash paid to Federal and State Taxing Authorities arising from the withholding of common shares from officers’ vested restricted stock grant issuance and issuance of Treasury Stock and the reversal of outstanding stock subscription receivable

On September 1, 2017, 19,465 shares of the Company’s restricted stock vested to Ms. Harness according to Ms. Harness’s employment agreement. The total taxable compensation to Ms. Harness for the 19,465 vested shares was $14,000, which is priced at the closing stock price on September 1, 2017 at $0.705 a share.

The Company issued 12,409 common shares (net share issuance amount), which is approximately 64% of the total vested common share amount of 19,465 common shares due to be issued to Ms. Harness. The remaining 7,056 shares of common stock were withheld from Ms. Harness for the payment of payroll taxes to the Federal and State taxing authorities and these shares withheld are being reported by the Company as treasury stock, at cost, on the Company’s accompanying balance sheets.

On December 22, 2017, 533,334 shares of the Company’s restricted stock vested to Dr. Bertolino according to Dr. Bertolino’s employment agreement. The total taxable compensation to Dr. Bertolino for the 533,334 vested shares was $373,334, which is priced at the closing stock price on December 21, 2017 at $0.7 a share.

16

The Company issued 295,286 common shares (net share issuance amount), which is approximately 55% of the total vested common share amount of 533,334 common shares due to be issued to Dr. Bertolino. The remaining 238,048 shares of common stock were withheld from Dr. Bertolino for the payment of payroll taxes to the Federal and State taxing authorities and these shares withheld are being reported by the Company as treasury stock, at cost, on the Company’s accompanying balance sheets.

In addition, the Company reversed an outstanding stock subscription receivable of $26,000 for 60,000 shares of common stock and recorded this amount as the cost of treasury stock.

On February 1, 2018, 3,333 shares of the Company’s restricted stock vested to Ms. Anne Ponugoti according to Ms. Ponugoti’s employment agreement. The total taxable compensation to Ms. Ponugoti for the 3,333 vested shares was $2,433, which is priced at the closing stock price on January 31, 2018 at $0.73 a share. The Company issued 2,645 common shares (net share issuance amount), which is approximately 79% of the total vested common share amount of 3,333 common shares due to be issued to Ms. Ponugoti. The remaining 688 shares of common stock were withheld from Ms. Ponugoti for the payment of payroll taxes to the Federal and State taxing authorities.

On February 5, 2018, the Board of Directors approved the retirement of 567,872 shares of its common stock in treasury, which shares are issued but are not outstanding. These shares included the 688 shares withheld from Ms. Ponugoti, as a result, all treasury shares of the Company were retired.

There were 0 shares and 262,080 shares of treasury stock outstanding at March 31, 2018 and June 30, 2017, respectively, purchased at a total cumulative cost of $0 and $220,000 at March 31, 2018 and June 30, 2017, respectively.

Restricted Stock Awards Outstanding

The following summarizes our restricted stock activity for our restricted stock issuances:

				Weighted
				Average
				Grant
	Number of			Date Fair
	Shares			Value
Total awards outstanding at June 30, 2017		601,728		$	1.39
Total shares granted		1,125,061			0.71
Total shares vested		(556,132	)		1.40
Total shares forfeited
Total unvested shares outstanding at March 31, 2018		1,170,657		$	0.73

Scheduled vesting for outstanding restricted stock awards at March 31, 2018 is as follows:

	Year Ending June 30,
	2018		2019		2020		2021		Total
Scheduled vesting		0		575,596		575,597		19,464		1,170,657

As of March 31, 2018, there was approximately $0.6 million of net unrecognized compensation cost related to unvested restricted stock-based compensation arrangements. This compensation is recognized on a straight-line basis resulting in approximately $0.4 million of compensation expected to be expensed over the next twelve months, and the total unrecognized stock-based compensation expense having a weighted average recognition period of 1.48 years.

17

For the nine months ended March 31, 2017

Issuances of Common Stock and Stock Options – Pursuant to New Employment Agreements

On June 27, 2016, the Company and Dr. Bertolino entered into an executive employment agreement as our President and Chief Medical Officer of the Company, effective on June 27, 2016 and the Company agreed to grant to Dr. Bertolino under the Company’s 2016 Equity Incentive Plan (i) 1,066,667 shares of restricted stock and (ii) a ten-year option to purchase 617,839 shares of the Company’s Class A common stock at an exercise price of $1.39 per share. Both shares and options shall vest upon the earliest to occur of the following: (1) 50% upon the first anniversary of the effective date, and the remaining 50% upon the second anniversary of the effective date (2) completion of both a Phase 2b psoriasis study and a Phase 2 oral mucositis study; (3) the Company’s common stock closes above $3.00 per share (as may be adjusted for any stock splits or similar actions); (4) the commencement of trading of the Company’s common stock on a national securities exchange (e.g. Nasdaq or the NYSE); or (5) upon a Change in Control of the Company (as defined in the employment agreement). The 1,066,667 shares were valued at approximately $1.5 million, which will be amortized over two years to June 27, 2018. The 617,839 stock options valued at approximately $800,000 and will be exercisable for 10 years at an exercise price of $1.39 per share. During the three months and nine months ended March 31, 2018, the Company recorded approximately $0 and $1,134,000 of total stock-based compensation, respectively. There was no stock-based compensation expense for the three months ended March 31, 2018 for it was fully expensed. The $1,134,000 of stock-based compensation expense for the nine months ended March 31, 2018 included approximately $396,000 of stock option expense and $738,000 of stock awards.

In December, 2017 and October, 2017, respectively, the Company was able to conclude both the Phase 2b psoriasis study and a Phase 2 oral mucositis study; therefore the remaining 50% of the shares and options vested to Dr. Bertolino, and all remaining shares and options granted on June 27, 2016 were fully amortized and expensed in December, 2017.

On July 18, 2016, the Company issued 7,500 stock options to purchase shares of the Company’s common stock to a consultant for services rendered, exercisable for 3 years at $1.38 per share of common stock. The value of these 7,500 options was approximately $4,000. During the three months ended September 30, 2016, the Company recorded approximately $4,000 of stock option expense for this option grant.

On September 1, 2016, the Company and Ms. Harness entered into an executive employment agreement as the Company’s VP, Clinical Sciences and Portfolio Management, effective on September 1, 2016. Commencing on September 1, 2016, the Company agreed to pay Ms. Harness an annual salary of $250,000. In addition, the Company agreed to grant to Ms. Harness, under the 2016 Plan (i) 58,394 shares of restricted stock, which shall vest upon the earliest to occur of the following: (1) one third upon the first anniversary of the effective date, one-third upon the second anniversary of the effective date, and the remaining one-third upon the third anniversary of the effective date; or (2) upon a Change in Control (as defined in the employment agreement) of the Company, and (ii) ten-year options to purchase 172,987 shares of the Company’s common stock were also granted at an exercise price of $1.37 per share, which shall vest upon the earliest to occur of the following: (1) one-third upon the first anniversary of the effective date, and the remaining balance vesting monthly in equal portions over the following 24 months; and (2) upon a Change in Control (as defined in the employment agreement) of the Company. The 58,394 shares were valued at approximately $80,000, which will be amortized over three years to September 1, 2019. The 172,987 stock options were valued at approximately $220,000 and will be exercisable for 10 years at an exercise price of $1.37 per share. They will be amortized over 3 years to September 1, 2019. During the three months and nine months ended March 31, 2018, the Company recorded approximately $25,000 and $75,000 of total stock-based compensation, respectively. The $25,000 of stock-based compensation expense for the three months ended March 31, 2018 included approximately $18,000 of stock option expense and $7,000 of stock awards. The $75,000 of stock-based compensation expense for the nine months ended March 31, 2018 included approximately $54,000 of stock option expense and $21,000 of stock awards.

Exercise of options

During the three months and nine months ended March 31, 2018 and 2017, there were no stock options exercised.

18

Note 11. Equity Transactions

$30 million Class A Common Stock Purchase Agreement with Aspire Capital

On September 6, 2017, the Company entered into a common stock purchase agreement with Aspire Capital, which replaced the prior 2015 $30 million Aspire Capital stock purchase agreement and provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company’s common stock over the 36-month term of the Stock Purchase Agreement. The Company issued 300,000 shares of its Class A common stock to Aspire Capital as a commitment fee. The commitment fee of approximately $215,000 is amortized pro-rata as the funding is received. The amortized amount of $41,000 was recorded to additional paid-in capital for the nine months ended March 31, 2018. The unamortized portion is carried on the balance sheet as deferred offering costs and was $173,000 at March 31, 2018. The Company registered the sale of all shares that Aspire Capital will purchase under this common stock purchase agreement. To the extent Aspire Capital purchases shares under this Purchase Agreement and subsequently sells those shares purchased, the other holders of shares of our Class A common stock may experience dilution, which may be substantial. In addition, the sale of a substantial number of shares of our Class A common stock by Aspire Capital, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we might otherwise wish to effect sales.

During the period from September 6, 2017 to March 31, 2018, the Company generated proceeds of approximately $5.7 million under the new 2017 agreement with Aspire Capital from the sale of approximately 8.7 million shares of its common stock. As of March 31, 2018, the available balance under the new equity line agreement was approximately $24.3 million.

On March 30, 2015, the Company entered into its prior common stock purchase agreement with Aspire Capital, which provided that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $30.0 million of the Company’s common stock over the 36-month term of the Purchase Agreement. In consideration for entering into this stock purchase agreement, the Company issued to Aspire Capital 160,000 shares of its Class A common stock as a commitment fee. The commitment fee of approximately $499,000 was amortized as the funding was received. The unamortized portion of deferred offering costs from this stock purchase agreement of $227,000 was recorded to additional paid-in capital in September, 2017, since the Company entered into a new $30 million common stock purchase agreement with Aspire Capital, to replace this prior $30 million 2015 Aspire Capital agreement, on September 6, 2017. During the period from July 1, 2017 to September 5, 2017, the Company generated proceeds of approximately $2.1 million under this 2015 agreement with Aspire Capital, from the sale of approximately 2.6 million shares of its common stock.

Note 12. Subsequent Events

Equity Transactions

From April 1, 2018 to May 9, 2018, the Company has generated additional proceeds of approximately $2.0 million under the Common Stock Purchase Agreement with Aspire Capital from the sale of approximately 8.0 million shares of its common stock.

19

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and plan of operations should be read in conjunction with the financial statements and the notes to those statements included in this Form 10-Q. This discussion includes forward-looking statements that involve risk and uncertainties. You should review our important note about forward-looking statements preceding the financial statements in Item 1 of this Part I. As a result of many factors, such as those set forth under “Risk Factors” in this Form 10-Q and in our Annual Report on Form 10-K, actual results may differ materially from those anticipated in these forward-looking statements.

Management’s Plan of Operation

Overview

Innovation Pharmaceuticals Inc. is a clinical stage biopharmaceutical company developing innovative therapies for inflammatory diseases, oncology, dermatology, and anti-infectives applications. The Company owns the rights to numerous drug compounds, including Brilacidin, our lead drug in a new class of compounds called defensin-mimetics; Kevetrin (thioureidobutyronitrile), our lead anti-cancer compound; and Prurisol (KM-133), which is in development for psoriasis.

Effective June 5, 2017, the Company changed its name from Cellceutix Corporation to Innovation Pharmaceuticals Inc.

The Company devotes most of its efforts and resources on business development and the clinical trials of its compounds.

Business Development Activities

The Company is engaged in discussions and negotiations regarding the out-licensing of its mid-stage, first-in-class clinical assets to global and/or specialty pharmaceutical companies who have expressed an interest in one or more assets in our pipeline. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties.

Recently, we released results from our completed Phase 2 Brilacidin study on Oral Mucositis. The results have attracted inquiries, additional confidential disclosure agreements, and discussions with pharmaceutical companies.

Clinical Development Programs

We anticipate using our expertise to manage and perform what we believe are the most critical aspects of the product development process which include: (i) design and oversight of clinical trials; (ii) development and execution of strategies for the protection and maintenance of intellectual property rights; and (iii) interactions with regulatory authorities domestically and internationally. We expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials.

Compound	Target/Indication	Clinical Status
Brilacidin	Oral Mucositis	Phase 2 (Completed; Fast Track Designation)
	Inflammatory Bowel Disease	Phase 2 (Completed; Proof of Concept Study)
	*ABSSSI	Phase 2b (Completed; **QIDP; Fast Track Designation)
Kevetrin	Ovarian Cancer	Phase 2 (Completed; Orphan Drug Designation)
Prurisol	Psoriasis	Phase 2b (Completed)

________________

*ABSSSI- Acute Bacterial Skin and Skin Structure Infection **Qualified Infectious Disease Product

20

Recent Developments

In early 2018, the Company approved steps to focus its efforts on clinical trials for its lead drug candidates. The Company’s office and laboratory needs have shifted from compound discovery to clinical development programs. The Company is now in the process of searching sites for its future headquarters.

The Company’s common stock traded under the stock symbol “CTIX” on the OTCQB until the market close of June 8, 2017. As of June 9, 2017, trading on the OTCQB began under the new Innovation Pharmaceuticals name and ticker symbol “IPIX”.

We are a clinical stage company. We have no product sales to date and we will not receive any product revenue until we receive approval from the FDA or equivalent foreign regulatory agencies to begin marketing a pharmaceutical product. Developing pharmaceutical products, however, is a lengthy and very expensive process. Assuming we do not encounter any unforeseen safety or efficacy issues during the course of developing our product candidates, we do not expect to complete the development of a product candidate for several years, if ever.

Set forth below is an overview of our research and development efforts on Brilacidin, Kevetrin, and Prurisol during fiscal 2018 and through the date of this Quarterly Report on Form 10-Q. We have entered into multiple non-disclosure agreements with large and mid-sized pharmaceutical companies that enable us to continue ongoing discussions regarding potential partnering should the below trial results support such a relationship.

Brilacidin

This lead drug candidate is in a new immunomodulatory class with anti-inflammatory and antibiotic properties called defensin-mimetics. Modeled after Host Defense Proteins (HDPs), the “front-line” of defense in the immune system, it is a small, non-peptidic, synthetic molecule that kills pathogens swiftly and thoroughly. Just as importantly, Brilacidin also functions in a robust immunomodulatory capacity, lessening inflammation and promoting healing.

Topical Brilacidin Clinical Studies (Trials)

In October 2017, the Company completed, a double-blind Phase 2 clinical trial of Brilacidin-OM for the treatment of oral mucositis (OM). In July 2017, the Company completed an open-label Phase 2 Proof-of-Concept (PoC) trial for the treatment of ulcerative proctitis /proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Diseases (IBD).

Oral Mucositis (OM): This completed study was a randomized, double-blind, placebo-controlled, Phase 2 clinical trial of Brilacidin for the prevention and control of Oral Mucositis (OM) in patients receiving chemoradiation for treatment of Head and Neck Cancer. Analysis of patients who received at least 55 Gy cumulative units of radiation showed the use of Brilacidin-OM met its primary endpoint with a clearly reduced incidence of severe OM (SOM) (WHO Grade ≥ 3) compared to placebo. Brilacidin oral rinse also appeared to be safe and well-tolerated.

Overall results were:

· Reduced Incidence of severe OM (Primary Endpoint)

 

o Brilacidin 42.9%, Placebo 60.0% [Modified Intent to Treat (mITT) Population]

o Brilacidin 36.8%, Placebo 60.0% [Per Protocol (PP) Population]

· Delayed Onset of severe OM

 

o For those patients in the Brilacidin group who did experience severe OM, onset occurred generally later during radiation therapy. The clear separation between placebo and Brilacidin, as to time of onset of severe OM, can be seen in Kaplan-Meier curves.

· Reduced Duration of severe OM

  

o Median durations for Brilacidin in both the mITT and PP populations for ‘initial instance’ and overall calculations were 0.0 days, indicating that more than half of all patients on active treatment did not experience severe OM. Overall median durations for placebo were 3.0 days and 5.5 days for the mITT and PP populations, respectively.

21

Relative risk reduction in severe Oral Mucositis (WHO Grade ≥ 3) in the Brilacidin-OM treatment group from that seen in the control group ([incidence control- incidence active]/incidence control) was: 28.5% (mITT population) and 38.7% (PP population).

Brilacidin appeared to be more effective with a cisplatin chemotherapy regimen administered approximately every 21 days vs. weekly administration. Brilacidin reduced the incidence of severe OM (WHO Grade ≥3) in the subgroup of patients receiving cisplatin administered as a high-dose regimen (80-100 mg/m²) approximately every 21 days compared to placebo. For the mITT population, the incidence of severe OM in the placebo subgroup was 71.4%, whereas the incidence for the Brilacidin subgroup was reduced to 25.0% (p=0.048). For the PP population, the incidence of severe OM in the placebo subgroup was 72.7%, whereas the incidence for the Brilacidin subgroup was reduced to 14.3% (p=0.025). In addition, time to onset of severe OM was delayed with Brilacidin treatment compared to placebo, even more markedly in the 21-day cisplatin regimen subset.

The relative risk reduction in the incidence of severe OM, Brilacidin compared to placebo, for the approximately every 21 days cisplatin regimen subset is 65.0% (mITT population) and 80.3% (PP population).

The Company believes that Brilacidin-OM, with its granted Fast Track FDA designation, occupies a lead position among OM drug candidates currently advancing in competitive clinical pipelines.

Ulcerative proctitis /proctosigmoiditis (UP/UPS): The completed Phase 2a trial comprised of three sequential cohorts, with progressive dose escalation by cohort—Cohort A (6 patients) -50 mg, Cohort B (6 patients) - 100 mg, and Cohort C (5 patients) - 200 mg, respectively. Treatment with Brilacidin by daily enema administration was performed for 42 days. The Primary Efficacy Endpoint of Clinical Remission (accounting for Stool Frequency, Rectal Bleeding and Endoscopy Findings subscores) was met by the majority of patients across the cohorts. Brilacidin was generally well-tolerated. Patient Quality of Life (as assessed by the Short Inflammatory Bowel Disease Questionnaire or “SIBDQ”) showed notable improvements. Limited systemic exposure to Brilacidin was demonstrated as measured by plasma Brilacidin concentrations.

From these results, we see significant opportunities in more broadly treating Inflammatory Bowel Disease (IBD) with Brilacidin. Our development programs depending on available financial resources include new formulations (oral and foam type) with potential associated toxicology studies and clinical studies to be defined.

ABSSSI

In February 2016, the Company submitted a Special Protocol Assessment (SPA) request, along with a final protocol, to the FDA, for a Phase 3 clinical trial of Brilacidin for the treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). We received comments and considerations from the FDA for incorporation into our study design. Management has decided to delay its response to FDA due to the low price per share of our common stock and the approximate $30 million costs required for this study which would result in significant dilution to our shareholders. Our strategy for now is to achieve success with other trials and attract partnering opportunities with significant down-payments and milestone payments which can fund these trials.

Our expenditures on Brilacidin were approximately $1.5 million and $1.3 million during the nine months ended March 31, 2018 and 2017, respectively.

Kevetrin

Kevetrin, our lead anti-cancer compound, is a small molecule compound that modulates p53, a protein involved in controlling cell mutations. In the majority of all cancers, regardless of origin, the p53 pathway is mutated, compromising its anti-tumor functions. In particular, most epithelial ovarian cancer patients have high-grade serous cancer, characterized by near universal p53 gene abnormalities. Pre-clinical research has demonstrated Kevetrin’s unique mechanism of action to induce apoptosis, slow tumor progression and reduce tumor volume in many types of cancers, including lung, breast, colon, prostate, squamous cell carcinoma and a leukemia tumor model. The FDA has awarded Orphan Drug designations for Kevetrin for ovarian cancer, retinoblastoma and pancreatic cancer as well as Rare Pediatric Disease designation for Retinoblastoma.

22

The main objective of the Company’s completed Phase 2a trial of Kevetrin in treating late-stage ovarian cancer was to confirm the modulation by Kevetrin of p53 pathways in tumors, as well as monitoring the response of tumors to the treatment. This goal was met with positive data from the first patients treated, showing direct evidence of molecular pathways modulation in tumors. Modulation of the p53 protein was observed in response to administration of Kevetrin; pathways analyses also pointed to concomitant cell cycle modulation at the level of gene expression. The Company believes that further pathways details and clinical tumor responses would best be explored with more frequent and potentially higher systemic drug exposure. Pharmacokinetic data collected on Kevetrin during the initial Phase 1 clinical trial demonstrates that the compound has a short half-life of approximately two hours. Kevetrin’s short half-life makes it a compelling candidate for an oral drug delivery treatment for the main purpose of allowing simple daily, or multiple-times daily, administrations within or outside the hospital setting. Compared to injectable or intravenous treatments, oral therapy is the preferred drug delivery method of patients. Preliminary laboratory studies are encouraging and support the potential of developing an oral formulation, but there are no assurances made or implied that the Company will be successful in completing development of an oral formulation. The Company has completed approximately half the Toxicology studies to support progression to oral dosing in humans, but the remainder of this work is on hold until the Company secures additional resources.

Our expenditures on Kevetrin were approximately $0.3 million and $0.7 million during the nine months ended March 31, 2018 and 2017, respectively.

Prurisol

Prurisol, our lead anti-psoriasis drug candidate, is a small molecule compound acting on the principles of immune modulation and PRINS (Psoriasis susceptibility-related RNA Gene Induced by Stress) reduction that has been found to be effective against psoriasis in animal models, both in induced psoriasis as well as a xenograft model with human psoriatic tissue.

The Company recently completed a randomized, double-blind, parallel-group, placebo-controlled Phase 2b trial of Prurisol for patients with moderate to severe plaque psoriasis. The treatment group arms are Prurisol 300mg, Placebo, Prurisol 400mg (Ratio 3:3:1) with a treatment duration of twelve weeks.

We are currently awaiting data from the trial. Our expenditures on Prurisol were approximately $3.8 million and $2.7 million during the nine months ended March 31, 2018 and 2017, respectively.

Future expenditures on Prurisol will be determined by the trial results, when available.

Compounds with Activity Against Gram-Negative Bacteria and Fungi

As research at the Company is now focused on supporting its clinical trials, we have reduced costs associated with the licensing of intellectual property for gram-negative bacteria and anti-fungal compounds by returning our  patent portfolio titled “Compounds and Methods for Treating Candidiasis and Aspergillus Infections” back to the university co-licensor. The Company at this time does not have any active gram-negative  or anti-fungal programs and therefore has decided not to pay for the maintenance of these Patent Rights. The net book value of the impaired patent as of March 31, 2018 is not material.

Critical Accounting Policies and Estimates

Management’s discussion and analysis of financial condition and results of operations are based upon our accompanying financial statements, which have been prepared in conformity with U.S. GAAP, and which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. These estimates are the basis for our judgments about the carrying values of assets and liabilities, which in turn may impact our reported revenue and expenses. Our actual results could differ significantly from these estimates under different assumptions or conditions.

Please see Note 3 of Part I, Item 1 of this Quarterly Report on Form 10-Q for the summary of significant accounting policies. In addition, please see Part II, Item 7, “Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K for the year ended June 30, 2017. There have been no material changes to our critical accounting policies and estimates since our Annual Report on Form 10-K for the year ended June 30, 2017.

Recently Issued Accounting Pronouncements

Please see Note 3 to the Financial Statements, Significant Accounting Policies and Recent Accounting Pronouncements, in the accompanying notes to Financial Statements for a discussion of recent accounting pronouncements and their effect, if any, on our financial statements.

23

Results of Operations

We expect to incur losses from operations for the next few years. We expect to incur increasing research and development expenses, including expenses related to additional clinical trials for our proprietary programs. We expect that our general and administrative expenses will also increase in the future as we expand our business development, by adding employees, consultants, additional infrastructure and incurring other additional costs. Based upon our expected rate of expenditures over the next twelve months and beyond, we will need additional working capital to meet our anticipated clinical trial obligations and other working capital requirements.

For the three months ended March 31, 2018 and 2017

Revenue

We generated no revenue and incurred operating expenses of approximately $2.4 million and $3.9 million for the three months ended March 31, 2018 and 2017, respectively.

Research and Development Expenses for Proprietary Programs

Below is a summary of our research and development expenses for our proprietary programs by categories of costs for the three months ended March 31, 2018 and 2017, respectively (rounded to nearest thousand):

	For the three months ended				Change
	March 31				2018 vs. 2017
	2018		2017		$			%
Clinical studies and development research	$	1,040,000	$	2,119,000		(1,079,000	)		-51	%
Officers’ payroll and payroll tax expenses related to R&D Department		174,000		232,000		(58,000	)		-25	%
Employees payroll and payroll tax expenses related to R&D Department		192,000		392,000		(200,000	)		-51	%
Stock-based compensation - officers		144,000		283,000		(139,000	)		-49	%
Stock-based compensation - employees		41,000		48,000		(7,000	)		-15	%
Stock-based compensation - consultants		80,000		5,000		75,000			1,500	%
Depreciation and amortization expenses		105,000		103,000		2,000			2	%
Total	$	1,776,000	$	3,182,000		(1,406,000	)		-44	%

Research and development expenses for proprietary programs decreased during the three months ended March 31, 2018 primarily due to lower spending on our Brilacidin program and Prurisol program.

Officers’ payroll decreased due to the reduction in salary of one officer, which became effective on January 16, 2018. Clinical studies and development expenses may decrease in future reporting periods depending on the Company’s current and future financial liquidity.

Employees payroll and payroll tax expenses decreased during the three months ended March 31, 2018 related to fewer employees engaged in preclinical development in September, 2017, which led to the decrease in employees’ payroll during the quarter ended March 31, 2018.

24

Stock- based compensation - officers decreased during the three months ended March 31, 2018 primarily related to the stock-based compensation given to our new President and Chief Medical Officer on September 1, 2017 and the vesting milestones for the stocks and options granted to our President and Chief Medical Officer on June 27, 2016 became fully vested and expensed for the completed clinical trials in December, 2017.

Stock-based compensation- employee decreased during the three months ended March 31, 2018 due to the decrease in stock awards granted to employees during the quarter ended March 31, 2018 compared with the same period in 2017.

Stock-based compensation- consultant increased during the three months ended March 31, 2018 due to more stock awards were granted to consultants during the quarter ended March 31, 2018.

Our research and development expenses include costs related to preclinical and clinical trials, outsourced services and consulting, officers’ payroll and related payroll tax expenses, other wages and related payroll tax expenses, stock-based compensation, depreciation and amortization expenses. We manage our proprietary programs based on scientific data and achievement of research plan goals. Our scientists record their time to specific projects when possible; however, many activities occurring simultaneously benefit multiple projects and cannot be readily attributed to a specific project. Accordingly, the accurate assignment of time and costs to a specific project is difficult and may not give a true indication of the actual costs of a particular project. As a result, we do not report costs on an individual program basis.

General and Administrative Expenses

General and administrative expenses consist mainly of compensation and associated fringe benefits not included in cost of research and development expenses for proprietary programs and include other management, business development, accounting, information technology and administration costs, including patent filing and prosecution, recruiting, consulting and professional services, travel and meals, facilities, depreciation and other office expenses.

Below is a summary of our general and administrative expenses for the three months ended March 31, 2018 and 2017, respectively (rounded to nearest thousand):

	For the three months ended				Change
	March 31				2018 vs. 2017
	2018		2017		$			%
Insurance and health expense	$	112,000	$	127,000		(15,000	)		-12	%
Rent and utility expense		64,000		70,000		(6,000	)		-9	%
Other G&A		119,000		134,000		(15,000	)		-11	%
Total	$	295,000	$	331,000		(36,000	)		-11	%

General and administrative expenses decreased during the three months ended March 31, 2018 primarily related to decreases in promotion, advertising and office expenses.

Officers’ Payroll and Payroll Tax Expenses

Below is a summary of our Officers’ payroll and payroll tax expenses for the three months ended March 31, 2018 and 2017, respectively (rounded to nearest thousand):

	Three months ended				Change
	March 31				2018 vs. 2017
	2018		2017		$			%
Officers’ payroll and payroll tax expenses	$	132,000	$	138,000		(6,000	)		-4	%

Officers’ payroll and payroll tax expenses for the Company was decreased during the three months ended March 31, 2018 and 2017. The officers’ payroll and payroll tax expenses represented one officer’s payroll and payroll tax expenses and 10% of payroll and payroll tax expenses paid for Dr. Menon. The Company recorded 90% of payroll paid to Dr. Menon and the related payroll tax expenses under Research and Development Expense.

25

Professional Fees

Below is a summary of our Professional fees for the three months ended March 31, 2018 and 2017, respectively (rounded to nearest thousand):

	Three months ended				Change
	March 31,				2018 vs. 2017
	2018		2017		$			%
Audit, legal and professional fees	$	195,000		201,000		(6,000	)		-3	%

Professional fees decreased during the three months ended March 31, 2018 primarily related to decrease in legal fees.

Other Income (Expense)

Below is a summary of our other income (expense) for the three months ended March 31, 2018 and 2017, respectively (rounded to nearest thousand):

	Three months ended						Change
	March 31,						2018 vs. 2017
	2018			2017			$		%
Interest Income	$	-			-			-		-	%
Interest Expenses		(51,000	)		(51,000	)		-		-	%
Other Income (Expense), net	$	(51,000	)		(51,000	)		-		-	%

There was no change in interest income from bank deposits and there was no change in interest expenses paid on the note payable – related party (see Note 9 to the notes to the condensed financial statements).

Net Losses

We incurred net losses of $2.4 million and $3.9 million for the three months ended March 31, 2018 and 2017, respectively because of the above-mentioned factors.

For the nine months ended March 31, 2018 and 2017

Revenue

We generated no revenue and incurred operating expenses of approximately $11.4 million and $10.1 million for the nine months ended March 31, 2018 and 2017, respectively.

26

Research and Development Expenses for Proprietary Programs

Below is a summary of our research and development expenses for our proprietary programs by categories of costs for the nine months ended March 31, 2018 and 2017, respectively (rounded to nearest thousand):

	For the nine months ended				Change
	March 31,				2018 vs. 2017
	2018		2017		$			%
Clinical studies and development research	$	6,164,000	$	5,129,000	$	1,035,000			20	%
Officers’ payroll and payroll tax expenses related to R&D Department		615,000		685,000		(70,000	)		-10	%
Employees payroll and payroll tax expenses related to R&D Department		784,000		1,001,000		(217,000	)		-22	%
Stock-based compensation - officers		1,470,000		861,000		609,000			71	%
Stock-based compensation - employees		115,000		110,000		5,000			5	%
Stock-based compensation - consultants		80,000		55,000		25,000			45	%
Depreciation and amortization expenses		316,000		301,000		15,000			5	%
Total	$	9,544,000	$	8,142,000	$	1,402,000			17	%

Research and development expenses for proprietary programs increased during the nine months ended March 31, 2018 primarily due to higher spending on our Brilacidin program and Prurisol program.

Officers’ payroll decreased due to the 50% reduction in salary of one officer, which became effective on January 16, 2018. Clinical studies and development expenses may decrease in future reporting periods depending on the Company’s current and future financial liquidity.

Employees payroll and payroll tax expenses decreased during the nine months ended March 31, 2018 related to the decrease in employees during the nine months ended March 31, 2018.

Stock-based compensation - officers increased during the nine months ended March 31, 2018 primarily related to the stock-based compensation given to our President and Chief Medical Officer on September 1, 2017 and the stock and options granted to our President and Chief Medical Officer on June 27, 2016 that became fully vested and expensed due to the completed clinical trial milestones in December, 2017.

Stock-based compensation- employee increased during the nine months ended March 31, 2018 due to the increase in stock awards to employees during the nine months ended March 31, 2018 compared with the same period in 2017.

Stock-based compensation- consultants increased during the nine months ended March 31, 2018 due to granting more stock awards to consultants during the nine months ended March 31, 2018.

Our research and development expenses include costs related to preclinical and clinical trials, outsourced services and consulting, officers’ payroll and related payroll tax expenses, other wages and related payroll tax expenses, stock-based compensation, depreciation and amortization expenses. We manage our proprietary programs based on scientific data and achievement of research plan goals. Our scientists record their time to specific projects when possible; however, many activities occurring simultaneously benefit multiple projects and cannot be readily attributed to a specific project. Accordingly, the accurate assignment of time and costs to a specific project is difficult and may not give a true indication of the actual costs of a particular project. As a result, we do not report costs on an individual program basis.

General and Administrative Expenses

General and administrative expenses consist mainly of compensation and associated fringe benefits not included in cost of research and development expenses for proprietary programs and include other management, business development, accounting, information technology and administration costs, including patent filing and prosecution, recruiting, consulting and professional services, travel and meals, facilities, depreciation and other office expenses.

Below is a summary of our general and administrative expenses for the nine months ended March 31, 2018 and 2017, respectively (rounded to nearest thousand):

	For the nine months ended				Change
	March 31,				2018 vs. 2017
	2018		2017		$			%
Insurance and health expense	$	348,000	$	385,000		(37,000	)		-10	%
Rent and utility expense		191,000		200,000		(9,000	)		-5	%
Other G&A		350,000		452,000		(102,000	)		-23	%
Total	$	889,000		1,037,000		(148,000	)		-14	%

General and administrative expenses decreased during the nine months ended March 31, 2018 primarily related to decreases in promotion, advertising and office expenses.

27

Officers’ Payroll and Payroll Tax Expenses

Below is a summary of our Officers’ payroll and payroll tax expenses for nine months ended March 31, 2018 and 2017, respectively (rounded to nearest thousand):

	Nine months ended				Change
	March 31,				2018 vs. 2017
	2018		2017		$			%
Officers’ payroll and payroll tax expenses	$	392,000	$	398,000	$	(6,000	)		-2	%

Officers’ payroll and payroll tax expenses for the Company was decreased during the nine months ended March 31, 2018 and 2017. The officers’ payroll and payroll tax expenses represented one officer’s payroll and payroll tax expenses and 10% of payroll and payroll tax expenses paid for Dr. Menon. The Company recorded 90% of payroll paid to Dr. Menon and the related payroll tax expenses under Research and Development Expense.

Professional Fees

Below is a summary of our Professional fees for the nine months ended March 31, 2018 and 2017, respectively (rounded to nearest thousand):

	Nine months ended				Change
	March 31,				2018 vs. 2017
	2018		2017		$			%
Audit, legal and professional fees	$	525,000	$	562,000	$	(37,000	)		-7	%

Professional fees decreased during the nine months ended March 31, 2018 primarily related to decrease in legal fees.

Other Income (Expense)

Below is a summary of our other income (expense) for the nine months ended March 31, 2018 and 2017, respectively (rounded to nearest thousand):

	Nine months ended						Change
	March 31,						2018 vs. 2017
	2018			2017			$			%
Interest Income	$	1,000		$	2,000		$	(1,000	)		-50	%
Interest Expenses		(152,000	)		(152,000	)		-			-	%
Other Income (Expense), net	$	(151,000	)	$	(150,000	)	$	(1,000	)		1	%

There was slight decrease in interest income from bank deposits and there was no change in interest expenses paid on the note payable – related party (see Note 9 to the notes to the condensed financial statements).

Net Losses

We incurred net losses of $11.5 million and $10.3 million for the nine months ended March 31, 2018 and 2017, respectively because of the above-mentioned factors.

28

Liquidity and Capital Resources

Projected Future Working Capital Requirements - Next Twelve Months

As of March 31, 2018, we had approximately $1.3 million in cash compared to $4.1 million of cash as of June 30, 2017. We have raised approximately $2.0 million from our stock purchase agreement with Aspire Capital from April 1, 2018 to the date of this filing. We have raised approximately $7.8 million from the sale of our common stock for the nine months ended March 31, 2018.

We anticipate that future budget expenditures may be approximately $12.2 million for the next twelve months, including approximately $8.2 million for clinical activities, supportive research, and drug product development. We will require additional sources of capital during fiscal years 2018 and 2019 in order to meet these budgeted working capital requirements. This assessment is based on current estimates and assumptions regarding our clinical development programs and business needs. Actual working capital requirements could differ materially from this above working capital projection. We will presently need to significantly reduce our spending on our clinical development programs as we do not have the adequate financial resources, as of the date of this filing, to fully execute our clinical programs.

We are actively engaged in licensing discussions with global pharmaceutical companies. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties. There can be no assurance that the Company will be successful in these business development activities.

On September 6, 2017, the Company entered into a $30 million common stock purchase agreement with Aspire Capital which replaced the prior $30 million Aspire Capital stock purchase agreement and provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company’s common stock over the 36-month term of the Purchase Agreement. During the period from September 6, 2017 to March 31, 2018, the Company has generated proceeds of approximately $5.7 million under this agreement with Aspire Capital from the sale of approximately 8.7 million shares of its common stock. As of March 31, 2018 the available balance is approximately $24.3 million. Our ability to continue to fund our research and development activities and corporate overhead expenses and continue as a going concern has been and continues to be dependent on this stock purchase agreement or similar agreements with Aspire Capital.

Our ability to successfully raise sufficient funds through the sale of equity securities, when needed, is subject to many risks and uncertainties and even if we are successful, future equity issuances would result in dilution to our existing stockholders. Our risk factors are described under the heading “Risk Factors” in Part I, Item 1A and elsewhere in our Annual Report on Form 10-K we filed with the SEC on September 11, 2017 and in other reports.

We have been successful at raising capital in the past but there can be no assurance that additional capital will be available on terms acceptable to us or in amounts sufficient to meet our needs. In the event that we are unable to raise sufficient capital from our current financing agreement with Aspire Capital when needed or secure additional sources of funding from others, we may be required to reduce our current rate of spending through reductions in staff and delaying, scaling back or stopping certain research and development programs, including the more costly Phase 2 clinical trials and potential future Phase 3 clinical trials on our wholly-owned development programs, as these clinical trials progress into a later stage of development or severely curtail our operations or otherwise impede our ongoing business efforts, or we could be forced to cease operations altogether. Insufficient liquidity may also require us to relinquish greater rights to product candidates at an earlier stage of development or on less favorable terms to us and our stockholders than we would otherwise choose in order to obtain up-front license fees needed to fund operations. These liquidity events could prevent us from successfully executing our current operating plan.

$75 Million Shelf Registration Statement

The Company has an effective shelf registration statement on Form S-3, registering the sale of up to $75 million of the Company’s securities. The Company filed the Form S-3 with the SEC on September 11, 2017, which included registering the shares underlying the 2017 $30 million Aspire Capital stock purchase agreement. Pursuant to the instructions to Form S-3, if the Company’s non-affiliate market capitalization as of an applicable measurement time, such as upon the filing of the Company’s Annual Report on Form 10-K, does not equal or exceed $75 million, the Company will be unable to offer and sell securities from its effective shelf registration statement on Form S-3, and the Company will have to use a registration statement for which it is eligible, such as Form S-1, to offer and sell securities.

29

Cash Flows

The following table provides information regarding our cash position, cash flows and capital expenditures for the nine months ended March 31, 2018 and 2017 (rounded to nearest thousand):

	Nine Months Ended						% Change
	March 31						Increase/
	2018			2017			(Decrease)
Net cash used in operating activities	$	(10,362,000	)	$	(7,949,000	)		30	%
Net cash used in investing activities		(108,000	)		(319,000	)		(66	)%
Net cash provided by financing activities		7,665,000			7,571,000			1	%
Net decrease in cash	$	(2,805,000	)	$	(697,000	)		(302	)%

Operating activities

The increase in net cash used in operating activities of $2.4 million versus the prior-year nine-month period was mainly due to increase in our losses from operations of $1.2 million as adjusted for the changes in our working capital accounts.

Investing activities

The decrease in net cash used in investing activities of $0.2 million versus the prior-year nine-month period was mainly due to decrease in purchases of patents of $0.2 million.

During the nine months ended March 31, 2018, our investing activities used cash of $0.1 million, mainly including the purchases of patents of $0.1 million.

During the nine months ended March 31, 2017, our investing activities used cash of $0.3 million, mainly including the purchases of patents of $0.3 million.

Financing activities

The increase in net cash provided by financing activities of approximately $0.1 million versus the prior-year nine-month period was due to an increase in sales of shares of our common stock to Aspire Capital.

During the nine months ended March 31, 2018, we raised approximately $7.8 million in net cash proceeds from the sale of 11.3 million shares of our common stock to Aspire Capital offset by cash paid to taxing authorities arising from the withholding of shares from employees of $172,000.

During the nine months ended March 31, 2017, we raised approximately $7.6 million in net cash proceeds, including $5.4 million in net proceeds from the sale of 5.3 million shares of our common stock to Aspire and $2.2 million in net proceeds from the sale of 2.5 million shares of our common stock at $0.89 per share in a registered direct offering, without an underwriter or placement agent on March 28, 2017.

Requirement for Additional Working Capital

The Company plans to incur total expenses of approximately $12.2 million for the next twelve months, including approximately $8.2 million for clinical activities, supportive research, and drug product development. The Company has limited experience with pharmaceutical drug development. As such, the budget estimate may not be accurate. In addition, the actual work to be performed is not known at this time, other than a broad outline, as is normal with any scientific work. As further work is performed, additional work may become necessary or a change in plans or workload may occur. Such changes may have an adverse impact on our estimated budget and on our projected timeline of drug development.

30

The Company will be unable to proceed with its planned drug development programs, meet its administrative expense requirements, capital costs, or staffing costs if it is not successful with its business development efforts or without accessing its financing available with Aspire Capital of approximately $24.3 million as of March 31, 2018. Management has put in place this new 2017 stock purchase agreement with Aspire Capital to fund its future clinical trial expenses and overhead expenses over the next twelve months. This purchase agreement provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company’s common stock over the 36-month term of the Purchase Agreement. Management believes, as of the date of this filing that the funding amount from Aspire Capital will be available as needed by the Company. Adverse market conditions in the Company’s per share price of its common stock and its trading volume may prevent the Company from funding its working capital requirements as needed.

In the event that we are unable to generate sufficient cash from our Aspire Capital purchase agreement or raise additional funds from others, we will be required to delay, reduce or severely curtail our operations or otherwise impede our on-going business efforts, which could have a material adverse effect on our future business, operating results, financial condition and long-term prospects. The Company expects to seek to obtain additional funding through business development activities (i.e. licensing and partnerships) and future equity issuances. There can be no assurance as to the availability or terms upon which such financing and capital might be available to us.

Contractual Obligations

Below is a table that presents our contractual obligations and commercial commitments as of March 31, 2018 (rounded to the nearest million):

	Payments Due by Period
	Total		Less than One Year		2 Year		3-5 Years		More than 5 Years
CRO obligations (1)	$	1.0	$	1.0	$	-	$	-	$	-
Lease obligations (2)	$	0.2	$	0.1	$	0.1	$	-	$	-
Total	$	1.2	$	1.1	$	0.1	$	-	$	-

___________ 

(1)

The Company has contractual minimum commitments to Contract Research Organizations of $1.0 million as of March 31, 2018.

(2)

The Company signed a lease extension agreement with Cummings Properties which began on October 1, 2013. The lease is for a term of five years ending on September 30, 2018, and requires monthly payments of approximately $18,000. The Company will receive $900 per month from the sublease of 200 square feet of space to Innovative Medical Research Inc., a company owned by Leo Ehrlich and Dr. Krishna Menon, officers of our Company, which is not included in the table above.

Equity Transactions

From April 1, 2018 to May 6, 2018, the Company has generated additional proceeds of approximately $2.0 million under the Common Stock Purchase Agreement with Aspire Capital from the sale of approximately 8.0 million shares of its common stock.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements, as defined in Item 304(a)(4)(ii) of Regulation S-K.

31

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company maintains an investment portfolio in accordance with our investment policy. The primary objectives of our investment policy are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields. The Company holds investments that are subject to credit risk, but not interest rate risks. The Company does not own derivative financial instruments in our investment portfolio. Accordingly, the Company does not believe there is any material market risk exposure that would require disclosure under this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We have established disclosure controls and procedures to ensure that the information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

As of March 31, 2018, management, with the participation of our principal executive officer and principal financial officer, carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act). Based on such evaluation, as of March 31, 2018, the principal executive officer and principal financial officer of the Company have concluded that the Company’s disclosure controls and procedures are effective.

Changes in Internal Controls

There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2018, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

32

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None

ITEM 1A. RISK FACTORS

Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended June 30, 2017, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common and capital stock. There have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended June 30, 2017.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURES

None

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

(a) Exhibit index

(1) The documents set forth below are filed herewith or incorporated herein by reference to the location indicated.

33

EXHIBIT INDEX

Exhibit No.	Title	Method of Filing
31.1	President of Research Certifications required under Section 302 of the Sarbanes Oxley Act of 2002	Filed herewith
31.2	Chief Executive Officer and Chief Financial Officer Certifications required under Section 302 of the Sarbanes Oxley Act of 2002	Filed herewith
32.1	President of Research Certifications required under Section 906 of the Sarbanes Oxley Act of 2002	Furnished herewith
32.2	Chief Executive Officer and Chief Financial Officer Certifications required under Section 906 of the Sarbanes Oxley Act of 2002	Furnished herewith
101	The following materials from the Company’s Quarterly Report on Form 10-Q for the nine months ended March 31, 2018 formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Statements of Income, (ii) the Condensed Statements of Comprehensive Income, (iii) the Condensed Balance Sheets, (iv) the Condensed Statements of Cash Flows, and (v) related notes	Filed herewith

34

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	INNOVATION PHARMACEUTICALS INC.
Dated: May 10, 2018	By:	/s/ Leo Ehrlich
		Leo Ehrlich
		Chief Executive Officer and Chief Financial Officer (Principal Executive, Accounting and Financial Officer)

By:	/s/ Krishna Menon
	Krishna Menon
	President of Research

35

EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, Krishna Menon, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Innovation Pharmaceuticals Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 10, 2018	By:	/s/ Krishna Menon
		Krishna Menon
		President of Research

EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, Leo Ehrlich, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Innovation Pharmaceuticals Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 10, 2018	By:	/s/ Leo Ehrlich
		Leo Ehrlich
		Chief Executive Officer and Chief Financial Officer (Principal Executive, Accounting and Financial Officer)

EX-32.1

EXHIBIT 32.1 

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Innovation Pharmaceuticals Inc., a Nevada corporation (the "Company"), does hereby certify, to such officer's knowledge, that: 

The Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company. 

A signed original of this written statement required by Section 906 has been provided to Innovation Pharmaceuticals Inc. and will be retained by Innovation Pharmaceuticals Inc. and furnished to the Securities and Exchange Commission or its staff upon request. 

Dated: May 10, 2018	By:	/s/ Krishna Menon
		Krishna Menon
		President of Research

EX-32.2

EXHIBIT 32.2

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Innovation Pharmaceuticals Inc., a Nevada corporation (the "Company"), does hereby certify, to such officer's knowledge, that: 

The Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company. 

A signed original of this written statement required by Section 906 has been provided to Innovation Pharmaceuticals Inc. and will be retained by Innovation Pharmaceuticals Inc. and furnished to the Securities and Exchange Commission or its staff upon request. 

Dated: May 10, 2018	By:	/s/ Leo Ehrlich
		Leo Ehrlich
		Chief Executive Officer and Chief Financial Officer and Chairman of the Board of Directors (Principal Executive, Accounting and Financial Officer)

XML

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2018	May 06, 2018
Document And Entity Information
Entity Registrant Name	INNOVATION PHARMACEUTICALS INC.
Entity Central Index Key	0001355250
Trading Symbol	ipix
Current Fiscal Year End Date	--06-30
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Amendment Flag	false
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Entity Common Stock, Shares Outstanding		155,091,427

XML

CONDENSED BALANCE SHEETS - USD ($)	Mar. 31, 2018	Jun. 30, 2017
Current Assets:
Cash	$ 1,336,000	$ 4,141,000
Prepaid expenses	40,000	308,000
Security deposits	78,000
Subscription receivable		26,000
Total Current Assets	1,454,000	4,475,000
Other Assets:
Patents - net	4,032,000	4,212,000
Equipment - net	93,000	120,000
Deferred offering costs - net	173,000	227,000
Security deposits		78,000
Total Other Assets	4,298,000	4,637,000
Total Assets	5,752,000	9,112,000
Current Liabilities:
Accounts payable - (including related party payables of approximately $1,486,000 and 1,506,000, respectively)	4,122,000	4,699,000
Accrued expenses - (including related party accruals of approximately $25,000 and $38,000, respectively)	306,000	711,000
Accrued salaries and payroll taxes - (including related party accrued salaries of approximately $2,953,000 and $2,953,000, respectively)	3,017,000	3,144,000
Convertible note payable - related party	2,022,000	2,022,000
Total Current Liabilities	9,467,000	10,576,000
Total Liabilities	9,467,000	10,576,000
Commitments and contingencies (Note 7)
Stockholders' Deficiency
Preferred stock, $0.001 par value, 10,000,000 designated shares, no shares issued and outstanding
Additional paid-in capital	77,324,000	68,295,000
Accumulated deficit	(81,054,000)	(69,553,000)
Treasury Stock, at cost (0 shares and 262,080 shares as of March 31, 2018 and June 30, 2017, respectively)	0	(220,000)
Total Stockholders' Deficiency	(3,715,000)	(1,464,000)
Total Stockholders' Deficiency	5,752,000	9,112,000
Common Class A
Stockholders' Deficiency
Common Stock, Value	15,000	14,000
Common Class B
Stockholders' Deficiency
Common Stock, Value

XML

CONDENSED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2018	Jun. 30, 2017
Current Liabilities:
Accounts payable, related party payables (in dollars)	$ 1,486,000	$ 1,506,000
Accrued expenses, related party accruals (in dollars)	25,000	38,000
Accrued salaries, due to related parties (in dollars)	$ 2,953,000	$ 2,953,000
Stockholders' Equity
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares designated (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Treasury Stock value	0	262,080
Common Class A
Stockholders' Equity
Common Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, shares authorized (in shares)	300,000,000	300,000,000
Common Stock, shares issued (in shares)	147,091,427	135,536,501
Common Stock, shares outstanding (in shares)	147,091,427	135,274,421
Common Class B
Stockholders' Equity
Common Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, shares authorized (in shares)	100,000,000	100,000,000
Common Stock, shares issued (in shares)	0	0
Common Stock, shares outstanding (in shares)	0	0

XML

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Condensed Statements Of Operations
Revenues
Operating expenses:
Research and development expenses	1,776,000	3,182,000	9,544,000	8,142,000
General and administrative expenses	295,000	331,000	889,000	1,037,000
Officers' payroll and payroll tax expenses	132,000	138,000	392,000	398,000
Professional fees	195,000	201,000	525,000	562,000
Total operating expenses	2,398,000	3,852,000	11,350,000	10,139,000
Loss from operations	(2,398,000)	(3,852,000)	(11,350,000)	(10,139,000)
Other income (expenses)
Interest income			1,000	2,000
Interest expense	(51,000)	(51,000)	(152,000)	(152,000)
Total other income - net	(51,000)	(51,000)	(151,000)	(150,000)
Loss before provision for income taxes	(2,449,000)	(3,903,000)	(11,501,000)	(10,289,000)
Provision for income taxes
Net loss	$ (2,449,000)	$ (3,903,000)	$ (11,501,000)	$ (10,289,000)
Basic and diluted loss per share	$ (0.02)	$ (0.03)	$ (0.08)	$ (0.08)
Weighted average number of common shares outstanding	146,071,627	127,270,598	141,296,395	125,599,470

XML

CONDENSED STATEMENTS OF CASH FLOW (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (11,501,000)	$ (10,289,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock and stock options issued as payment for compensation, services rendered and financing costs	1,665,000	1,026,000
Amortization of patent costs	289,000	277,000
Depreciation of equipment	28,000	24,000
Changes in operating assets and liabilities:
Prepaid expenses and security deposits	268,000	165,000
Accounts payable	(578,000)	664,000
Accrued expenses	(406,000)	130,000
Accrued officers' salaries and payroll taxes	(127,000)	54,000
Net cash used in operating activities	(10,362,000)	(7,949,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property, plant and equipment		(63,000)
Patent costs	(108,000)	(256,000)
Net cash used in investing activities	(108,000)	(319,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Sales of common stock, net of offering costs	7,837,000	7,571,000
Purchase of treasury stock	(172,000)
Net cash provided by financing activities	7,665,000	7,571,000
NET DECREASE IN CASH	(2,805,000)	(697,000)
CASH, BEGINNING OF PERIOD	4,141,000	6,310,000
CASH, END OF PERIOD	1,336,000	5,613,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest	156,000	44,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH FLOW INVESTING AND FINANCING ACTIVITIES
Commitment shares issued as deferred offering costs	215,000
Reversal of subscription receivable to treasury stock	$ 26,000

XML

Basis of Presentation and Nature of Operations

9 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Note 1 - Basis of Presentation and Nature of Operations

Unaudited Interim Financial Information

The accompanying unaudited condensed financial statements of Innovation Pharmaceuticals Inc. have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or the SEC, including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements for the year ended June 30, 2017, included in our Annual Report on Form 10-K for the year ended June 30, 2017.

In the opinion of the management of Innovation Pharmaceuticals Inc., all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three-month and nine-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. When used in these notes, the terms “Company”, “we”, “us” or “our” mean Innovation Pharmaceuticals Inc.

Basis of Presentation and Name Change

Innovation Pharmaceuticals Inc. (the “Company”) was incorporated on August 1, 2005 in the State of Nevada. Effective June 5, 2017, the Company amended its Articles of Incorporation and changed its name from Cellceutix Corporation to Innovation Pharmaceuticals Inc. In accordance with Section 92A.180 of the Nevada Revised Statutes, stockholder approval of the name change was not required.

The Company is a clinical stage biopharmaceutical company and has no customers, products or revenues to date. The Company’s common stock is quoted on OTCQB, symbol “IPIX”.

Nature of Operations - Overview

We are in the business of developing innovative small molecule therapies to treat diseases with significant medical need, particularly in the areas of inflammatory diseases, cancer, dermatology and anti-infectives. Our strategy is to use our business and scientific expertise to maximize the value of our pipeline. We will do this by focusing initially on our lead compounds, Brilacidin, Kevetrin and Prurisol and advancing them as quickly as possible along the regulatory pathway. We will develop the highest quality data and broadest intellectual property to support our compounds.

We currently own all development and marketing rights to our products. In order to successfully develop and market our products, we may have to partner with other companies. Prospective partners may require that we grant them significant development and/or commercialization rights in return for agreeing to share the risk of development and/or commercialization.

XML

Going Concern and Liquidity

9 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Note 2 - Going Concern and Liquidity

As of June 30, 2017, the Company adopted Accounting Standards Codification 205-40. This guidance amended the existing requirements for disclosing information about an entity’s ability to continue as a going concern and explicitly requires management to assess an entity’s ability to continue as a going concern and to provide related disclosure in certain circumstances. This guidance was effective for annual reporting periods ending after December 15, 2016, and for annual and interim reporting periods thereafter. The following information reflects the results of management’s assessment, plans and conclusion of the Company’s ability to continue as a going concern.

We have incurred recurring losses since inception and expect to continue to incur losses as a result of costs and expenses related to our research and continued development of our compounds and our corporate general and administrative expenses. As of March 31, 2018, the Company has an accumulated deficit of approximately $81.1 million, representative of recurring losses since inception. The Company is a development stage pharmaceutical company that has no sales as it does not have any products in the market and will continue to not have any revenues until it begins to market its products after it has obtained the necessary Federal Drug Administration (the “FDA”) approval. As a result, the Company expects to continue to incur losses over the next 12 months from the date of this filing.

At March 31, 2018, the Company’s cash amounted to $1.3 million and current liabilities amounted to $9.5 million, of which $6.5 million were payables to related parties with no immediate payment terms (See Note 8- Related Party Transactions in the Notes to Condensed Financial Statements section below). The Company had expended substantial funds on its clinical trials and expects to continue our spending on research and development expenditures. The Company’s net cash used in operating activities for the nine months ended March 31, 2018 was approximately $10.4 million, and current projections indicate that the Company will have continued negative cash flows from operating activities for the foreseeable future. Our net losses incurred for the nine months ended March 31, 2018 and 2017, amounted to $11.5 million and $10.3 million, respectively, and we had a working capital deficit of approximately $8.0 million and $6.1 million, respectively at March 31, 2018 and June 30, 2017.

Accordingly, the Company’s planned operations, including total budgeted expenditures of approximately $12.2 million for the next twelve months, raise doubt about its ability to continue as a going concern. The Company’s plans to alleviate the doubt of its ability to continue as a going concern primarily include controlling the timing and spending on its research and development programs, thereby being able to decrease its current budgeted expenditures mentioned above for the next 12 months, as needed and to continue raising additional funds through equity financings from its common stock purchase agreement with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”). The Company may consider other plans to fund operations including: (1) raising additional capital through debt financings or from other sources; (2) additional funding through new relationships to help fund future clinical trial costs (i.e. licensing and partnerships); (3) reducing spending on one or more research and development programs by discontinuing development; and/or (4) restructuring operations to change its overhead structure. The Company may issue securities, including shares of common stock, shares of preferred stock and stock purchase contracts through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-3 filed with the SEC on September 11, 2017 and declared effective on September 21, 2017. Pursuant to the instructions to Form S-3, if the Company’s non-affiliate market capitalization as of an applicable measurement time, such as upon the filing of the Company’s Annual Report on Form 10-K, does not equal or exceed $75 million, the Company will be unable to offer and sell securities from its effective shelf registration statement on Form S-3.

The Company’s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.

The Company believes that the actions discussed above are probable of occurring and alleviating the substantial doubt raised by our historical operating results and satisfying our estimated liquidity needs twelve months from the issuance of the accompanying financial statements.

On September 6, 2017, the Company entered into a new $30 million common stock purchase agreement with Aspire Capital (the “2017 Agreement”) to replace the prior 2015 $30 million common stock purchase agreement with Aspire Capital (the “2015 Agreement”). During the period from July 1, 2017 to September 5, 2017, the Company generated proceeds of approximately $2.1 million under the 2015 Agreement from the sale of approximately 2.6 million shares of its common stock. During the period from September 6, 2017 to March 31, 2018, the Company generated proceeds of approximately $5.7 million under the 2017 Agreement from the sale of approximately 8.7 million shares of its common stock. As of March 31, 2018, the available balance under the 2017 Agreement is approximately $24.3 million.

XML

Significant Accounting Policies and Recent Accounting Pronouncements

9 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research accruals, recoverability of long-lived assets, measurement of stock-based compensation, and the periods of performance under collaborative research and development agreements. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.

Net Loss Per Share

Basic and diluted loss per share is computed based on the weighted-average common shares and common share equivalents outstanding during the period. Common share equivalents consist of stock options, convertible notes payable underlying shares and unvested restricted stock. Common share equivalents of 47 million and 46 million shares of common stock were excluded from the computation of diluted loss per share for the nine months ended March 31, 2018 and 2017, respectively, because we incurred net losses for the nine months ended March 31, 2018 and 2017, and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive and are therefore not included in the calculations.

Treasury Stock

The Company accounts for treasury stock using the cost method. There were 0 shares and 262,080 shares of treasury stock outstanding, purchased at a total cumulative cost of $0 and $220,000 at March 31, 2018 and June 30, 2017, respectively (see Note 10).

Treasury stock, representing shares of the Company’s common stock that have been acquired for payroll tax withholding on vested stock grants, is recorded at its acquisition cost and these shares are not considered outstanding.

Accounting for Stock Based Compensation

The stock-based compensation expense incurred by the Company for employees and directors in connection with its stock option plan is based on the employee model of ASC 718, and the fair market value of the options is measured at the grant date. Under ASC 718, an employee is defined as “An individual over whom the grantor of a share-based compensation award exercises or has the right to exercise sufficient control to establish an employer-employee relationship based on common law as illustrated in case law and currently under U.S. tax regulations”. Our consultants do not meet the employer-employee relationship as defined by the IRS and therefore are accounted for under ASC 505-50.

ASC 505-50-30-11 further provides that an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date:

i.	The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and
ii.	The date at which the counterparty’s performance is complete.

We have elected to use the Black-Scholes-Merton pricing model to determine the fair value of stock options on the dates of grant. Restricted stock is measured based on the fair market values of the underlying stock on the dates of grant. We recognize stock-based compensation using the straight-line vesting method over the requisite service period of the equity awards.

The components of stock-based compensation expense included in the Company’s Condensed Statements of Operations for the three months and nine months ended March 31, 2018 and 2017 are as follows (rounded to nearest thousand):

	Three months ended March 31				Nine months ended March 31
	2018		2017		2018		2017
Research and development expenses
Professional fees	$	80,000	$	5,000	$	80,000	$	55,000
Employees’ bonus		41,000		48,000		115,000		110,000
Officers’ bonus		144,000		283,000		1,470,000		861,000
Total stock-based compensation expense	$	265,000	$	336,000	$	1,665,000	$	1,026,000

Recent Adopted Accounting Pronouncements

Stock Compensation - In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which simplified the income tax consequences, accounting for forfeitures and classification on the Statement of Cash Flows with (i) excess tax benefits being classified as cash inflows provided by operating activities, and (ii) cash paid to taxing authorities arising from the withholding of shares from employees being classified as cash outflows used in financing activities. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016, with early adoption permitted. This new pronouncement was adopted on July 1, 2016 and did not have a material effect on the Company’s financial position or results of operations, but had an effect of the classification of cash paid to taxing authorities arising from the withholding of shares from employees (treasury stock), classified as cash outflows used in financing activities.

In June 2014, the FASB issued ASU 2014-12, “Compensation—Stock Compensation.” The amendments in this ASU apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target can be achieved after the requisite service period. This ASU is the final version of Proposed ASU EITF-13D, “Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period,” which has been deleted. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. As indicated in the definition of vest, the stated vesting period (which includes the period in which the performance target could be achieved) may differ from the requisite service period. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The implementation of this standard did not have a material impact on the Company’s accompanying condensed financial statements.

Recently Issued Accounting Guidance

In May 2014, the FASB issued authoritative guidance that defines how companies should report revenues from contracts with customers. The standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It provides companies with a five-step, principles-based model to use in accounting for revenue and supersedes current revenue recognition requirements, including most industry-specific and transaction-specific revenue guidance. In August 2015, the FASB deferred the effective date of the new revenue standard by one year. As a result, the new standard would not be effective for the Company until 2019. In addition, the FASB is allowing companies to early adopt this guidance for non-public entities beginning in fiscal year 2017. The guidance permits an entity to apply the standard retrospectively to all prior periods presented, with certain practical expedients, or apply the requirements in the year of adoption, through a cumulative adjustment. The Company will apply this new guidance when it becomes effective and has not yet selected a transition method. The Company, due to not having any revenue currently and in the foreseeable future, has concluded that the impact of the adoption of this accounting standard on its financial statements will not be material.

In February 2016, FASB issued ASU No. 2016-02, “Leases (Topic 842)”. The guidance requires that a lessee recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right of use asset representing its right to use the underlying asset for the lease term. The guidance requires the following for finance leases: the right-of-use asset and a lease liability will be initially measured at the present value of the lease payments, in the statement of financial position; interest on the lease liability will be recognized separately from amortization of the right-of-use asset in the statement of comprehensive income; and repayments of the principal portion of the lease liability will be classified within financing activities and payments of interest on the lease liability and variable lease payments within operating activities in the statement of cash flows. The guidance requires the following for operating leases: the right-of-use asset and a lease liability will be initially measured at the present value of the lease payments, in the statement of financial position; a single lease cost will be recognized, calculated so that the cost of the lease is allocated over the lease term on a generally straight-line basis; and all cash payments will be classified within operating activities in the statement of cash flows. Under Topic 842 the accounting applied by a lessor is largely unchanged from that applied under previous U.S. GAAP. The amendments in Topic 842 are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Management has determined that based on current accounting and lease contract information the adoption of ASU No. 2016-02 is not expected to have a significant impact on the Company’s financial position, results of operations and disclosures. However, management is continually evaluating the future impact of ASU No. 2016-02 based on changes in the Company’s financial statements through the period of adoption.

Intangibles, Goodwill and Other —In January 2017, the FASB issued ASU No. 2017-04, “Intangibles – Goodwill and Other (Topic 350) – Simplifying the Test for Goodwill Impairment” (“ASU No. 2017-04”). To simplify the subsequent measurement of goodwill, ASU No. 2017-04 eliminates Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, ASU No. 2017-04 requires an entity to perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. ASU No. 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore, the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU No. 2017-04 is effective for fiscal years beginning after December 15, 2019. The Company will adopt ASU No. 2017-04 commencing in the first quarter of fiscal 2021. The Company does not believe this standard will have a material impact on its financial statements or the related footnote disclosures.

Statement of Cash Flows — In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force)” (“ASU No. 2016-15”). ASU No. 2016-15 clarifies how certain cash receipts and payments should be presented in the statement of cash flows. ASU No. 2016-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company will adopt ASU No. 2016-15 commencing in the first quarter of fiscal 2019. The Company does not believe this standard will have a material impact on its financial statements or the related footnote disclosures.

XML

Patents, net

9 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Note 4 - Patents, net

Patents, net consisted of the following (rounded to nearest thousand):

	Useful life	March 31,			June 30,
	(years)	2018			2017
Purchased Patent Rights – Brilacidin, and related compounds	14	$	4,082,000		$	4,082,000
Purchased Patent Rights – Anti-microbial – surfactants and related compounds	12		144,000			144,000
Patents – Kevetrin and related compounds	17		1,417,000			1,308,000
			5,643,000			5,534,000
Less: Accumulated amortization for Brilacidin, Anti-microbial- surfactants and related compounds			(1,386,000	)		(1,158,000	)
Accumulated amortization for Patents –Kevetrin and related compounds			(225,000	)		(164,000	)
		$	4,032,000		$	4,212,000

The patents are amortized on a straight-line basis over the useful lives of the assets, determined to be 12-17 years from the date of acquisition.

Amortization expense was approximately $96,000 and $95,000, for the three months ended March 31, 2018 and 2017, respectively and was approximately $289,000, and $277,000 for the nine months ended March 31, 2018 and 2017, respectively.

At March 31, 2018, the future amortization period for all patents was approximately 7.43 years to 16.75 years. Future estimated annual amortization expenses are approximately $96,000 for the year ending June 30, 2018, $383,000 for each year from 2019 to 2025, $374,000 for the year ending June 30, 2026, $371,000 for the year ending June 30, 2027, $134,000 for the year ending June 30, 2028, $80,000 for the years ending June 30, 2029 through the years ended 2032, $41,000 for the year ending June 30, 2033, $10,000 for the year ending June 30, 2034 and $2,000 for the year ending June 30, 2035.

Compounds with Activity Against Gram-Negative Bacteria and Fungi

As research at the Company is now focused on supporting its clinical trials, we have reduced costs associated with the licensing of intellectual property for gram-negative bacteria and anti-fungal compounds by returning our patent portfolio titled “Compounds and Methods for Treating Candidiasis and Aspergillus Infections” back to the university co-licensor. The Company at this time does not have any active gram-negative or anti-fungal programs and therefore has decided not to pay for the maintenance of these Patent Rights. The net book value of the impaired patent as of March 31, 2018 is not material.

XML

Accrued Expenses

9 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Note 5 - Accrued Expenses

Accrued expenses consisted of the following (rounded to nearest thousand):

	March 31,		June 30,
	2018		2017
Accrued research and development consulting fees	$	281,000	$	673,000
Accrued rent (Note 8) – related parties		13,000		21,000
Accrued interest – (Note 9) related parties		12,000		17,000
Total	$	306,000	$	711,000

XML

Accrued Salaries and Payroll Taxes - Related Parties And Other

9 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Note 6 - Accrued Salaries and Payroll Taxes - Related Parties And Other

Accrued salaries and payroll taxes consisted of the following (rounded to nearest thousand):

	March 31,		June 30,
	2018		2017
Accrued salaries - related parties	$	2,823,000	$	2,823,000
Accrued payroll taxes - related parties		130,000		130,000
Accrued employee bonuses		-		86,000
Withholding tax - payroll		64,000		105,000
Total	$	3,017,000	$	3,144,000

XML

Commitments and Contingencies

9 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Note 7 - Commitments and Contingencies

Lease Commitments

Operating Leases – Rental Property

The Company signed a lease extension agreement with Cummings Properties which began on October 1, 2013. The lease is for a term of five years ending on September 30, 2018, and requires monthly payments of $18,000. Innovative Medical Research Inc., a company owned by Leo Ehrlich and Dr. Krishna Menon, officers of the Company, has co-signed the lease and subleases 200 square feet of space previously used by the Company and pays the Company $900 per month.

As of March 31, 2018, future minimum lease payments to Cummings Properties required under the non-cancelable operating lease are as follows (rounded to nearest thousand):

Year ending June 30,
2018	$	54,000
2019		54,000
Total minimum payments	$	108,000

Rent expense, net of lease income, under this operating lease agreement was approximately $53,000 and $52,000 for the three months ended March 31, 2018 and 2017, respectively and was approximately $157,000 and $153,000 for the nine months ended March 31, 2018 and 2017, respectively. Before September 2013, the Company paid rent to Kard Scientific for office space and details are shown at Note 8 - Related Party Transactions below.

Operating Leases - Equipment

We leased equipment under a non-cancelable operating lease that expired in April, 2018. As of March 31, 2018, there was no future minimum rental commitment for our operating lease for the next twelve months.

Contractual Commitments

The Company has total contractual minimum commitments of approximately $1.0 million to contract research organizations as of March 31, 2018. Expenses are recognized when services are performed by the contract research organizations.

XML

Related Party Transactions

9 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Note 8 - Related Party Transactions

Office Lease

Dr. Menon, the Company’s principal shareholder, President of Research, and Director, also serves as the Chief Operating Officer and Director of Kard Scientific (“KARD”). On December 7, 2007, the Company began renting office space from KARD, and since September 1, 2013, the Company no longer leases space from KARD. At March 31, 2018 and June 30, 2017, rent payable to KARD of approximately $13,000 and $21,000, respectively, were included in accrued expenses.

In September 2013, the Company signed a lease extension agreement with Cummings Properties for the company’s offices and laboratories at 100 Cummings Center, Suite 151-B Beverly, MA 01915. The lease is for a term of five years from October 1, 2013 to September 30, 2018 and requires monthly payments of approximately $18,000. The Company had taken over the space occupied by KARD. In addition, Innovative Medical Research Inc., (“Innovative Medical”) a company owned by Mr. Ehrlich and Dr. Menon, officers of the Company, has co-signed the lease and rents approximately 200 square feet of office space, the space previously used by the Company and pays the Company $900 per month, the same amount the Company previously paid KARD. Innovative Medical paid total rent of approximately $3,000 and $9,000 to the Company for both of the three months and nine months ended March 31, 2018 and 2017 and the rental payment was offset with the accrued rent owed to KARD.

Clinical Studies

The Company previously engaged KARD to conduct specified pre-clinical studies. The Company did not have an exclusive arrangement with KARD. All work performed by KARD needed prior approval by the executive officers of the Company, and the Company retained all intellectual property resulting from the services by KARD. The Company now has its own research study capabilities and no longer uses KARD. At March 31, 2018 and June 30, 2017, the accrued research and development expenses payable to KARD was approximately $1,486,000 and this amount was included in accounts payable.

Other related party transactions are disclosed in Note 9 below.

XML

Convertible Note Payable - Related Party

9 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Note 9 - Convertible Note Payable - Related Party

During the year ended June 30, 2010, Mr. Ehrlich loaned the Company a total of approximately $973,000. A condition for this note was that the Ehrlich Promissory Note A and Ehrlich Promissory Note B be replaced with a new note, Ehrlich Promissory Note C. The Ehrlich Promissory Note C is an unsecured demand note that bears 9% simple interest per annum and is convertible into the Company’s Class A common stock at $0.50 per share. The note requires that the interest rate on the amounts due on Ehrlich Promissory Notes A and B be changed retroactively, beginning October 1, 2009, to 9%. On April 1, 2011, the Company amended the Ehrlich Promissory Note C and agreed to retroactively convert accrued interest of approximately $97,000 through December 31, 2010 into additional principal. During the year ended June 30, 2011, Mr. Ehrlich loaned the Company an additional (approximate) $997,000 which brought the total balance of the demand note to approximately $2,002,000. During the year ended June 30, 2012, Mr. Ehrlich loaned the Company an additional $20,000 which brought the balance of this demand note to approximately $2,022,000.

On May 8, 2012, the Company did not have the ability to repay the Ehrlich Promissory Note C loan and agreed to change the interest rate on the outstanding balance of principal and interest of approximately $2,248,000, as of March 31, 2012, from 9% simple interest to 10% simple interest, and the Company issued 2,000,000 Equity Incentive Options exercisable at $0.51 per share equal to 110% of the closing bid price of $0.46 per share on May 7, 2012. Options are valid for ten (10) years from the date of issuance.

At March 31, 2018 and June 30, 2017, approximately $12,000 and $17,000, respectively, is the accrued interest payable on this note.

At March 31, 2018 and June 30, 2017, principal balance of this demand note was approximately $2,022,000.

XML

Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding

9 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Note 10 - Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding

Current Equity Incentive Plan

2016 Equity Incentive Plan

On June 30, 2016, the Board of Directors adopted the Company’s 2016 Equity Incentive Plan (the “2016 Plan”). The 2016 Plan became effective upon adoption by the Board of Directors on June 30, 2016.

Up to 20,000,000 shares of the Company’s Class A common stock may be issued under the 2016 Plan (subject to adjustment as described in the 2016 Plan); provided that (1) no Outside Director (as defined in the 2016 Plan) may be granted awards covering more than 250,000 shares of common stock in any year and (2) no participant shall be granted, during any one year period, options to purchase common stock and stock appreciation rights with respect to more than 4,000,000 shares of common stock in the aggregate or any other awards with respect to more than 2,500,000 shares of common stock in the aggregate. The 2016 Plan permits the grant of ISOs, non-qualified stock options, stock appreciation rights, restricted awards, performance share awards and performance compensation awards to employees, directors, and consultants of the Company and its affiliates.

In connection with adoption of the 2016 Plan, the Board of Directors also approved forms of Incentive Stock Option Agreement for Employees, Non-qualified Stock Option Agreement for Employees, Non-qualified Stock Option Agreement for Non-Employee Directors, Restricted Stock Award Agreement for Employees and Restricted Stock Award Agreement for Non-Employee Directors that will be utilized by the Company to grant options and restricted shares under the 2016 Plan.

Stock Options Issued and Outstanding

The following table summarizes all stock option activity under the Company’s equity incentive plans:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding at June 30, 2017		40,655,245		$	0.22		3.61	$	31,662,730
Granted		1,070,826			0.75		8.14
Forfeited/expired		(277,924	)		2.44
Outstanding at March 31, 2018		41,448,147			0.22		3.01	$	14,819,300
Exercisable at March 31, 2018		40,452,299			0.21		2.87	$	14,819,300

The fair value of options granted for the nine months ended March 31, 2018 and 2017 was estimated on the date of grant using the Black Scholes model that uses assumptions noted in the following table.

	Nine months ended
	March 31,
	2018	2017
Expected term (in years)	5 - 10	3 - 10
Expected stock price volatility	52.80% to 106.01%	57.63% to 111.62%
Risk-free interest rate	2.15% to 2.56%	0.71% to 2.49%
Expected dividend yield	0	0

Stock-Based Compensation

The Company recognized approximately $265,000 and $336,000 of total stock-based compensation costs related to stock and stock options awards for the three months ended March 31, 2018 and 2017, respectively. The Company recognized approximately $1,665,000 and $1,026,000 of total stock-based compensation costs related to stock and stock options awards for the nine months ended March 31, 2018 and 2017, respectively.

The $1,665,000 of total stock-based compensation expense for the nine months ended March 31, 2018 included approximately $677,000 of stock options expense and $988,000 of stock awards.

For the nine months ended March 31, 2018

On February 1, 2018, the Company agreed to issue options to purchase 75,000 shares of common stock to each of two consultants for specified services to be provided from February 1, 2018 to January 31, 2019 in accordance with agreements with the consultants. During the nine months ended March 31, 2018, the Company recorded approximately $8,000 of related stock-based compensation.

On February 10, 2017, the Company entered into verbal agreements with two consultants to issue options to purchase 50,000 shares of common stock and 75,000 shares of common stock, respectively, to the two consultants for services to be performed from February 13, 2017 to January 31, 2018 in accordance with their consulting agreements. The Company formally signed the agreements with the two consultants on March 13, 2018. During the nine months ended March 31, 2018, the Company recorded approximately $72,000 of related stock-based compensation.

On September 1, 2017, the Company agreed to grant to Dr. Arthur Bertolino, the President and Chief Medical Officer of the Company, under the 2016 Plan (i) 1,066,667 shares of restricted stock and (ii) a ten-year option to purchase 617,839 shares of the Company’s Class A common stock at an exercise price of $0.705 per share. Both shares and options shall vest upon the earliest to occur of the following: (1) 50% upon the first anniversary of the effective date and the remaining 50% upon the second anniversary of the effective date; (2) shares of the Company’s common stock close above $3.00 per share (as may be adjusted for any stock splits or similar actions); (3) the commencement of trading of shares of the Company’s common stock on a national securities exchange; or (4) upon a change in control of the Company. The 1,066,667 shares were valued at approximately $752,000 and the 617,839 stock options valued at approximately $399,000. Both shares and options will be amortized over 2 years to September 1, 2019 unless the probability of the other above vesting requirements occurring are met at an earlier date. At March 31, 2018, the Company determined that it was not probable that these accelerated vesting provisions would occur earlier than the scheduled vesting date. During the three months and nine months ended March 31, 2018, the Company recorded approximately $144,000 and $336,000 of total stock-based compensation, respectively. The $144,000 of stock-based compensation expense for the three months ended March 31, 2018 included approximately $50,000 of stock option expense and $94,000 of stock awards. The $336,000 of stock-based compensation expense for the nine months ended March 31, 2018 included approximately $117,000 of stock option expense and $219,000 of stock awards.

On September 1, 2017, the Company agreed to grant to Ms. Jane Harness, the Senior Vice President, Clinical Sciences and Portfolio Management of the Company under the 2016 Plan (i) 58,394 shares of restricted stock and (ii) a ten-year option to purchase 172,987 shares of the Company’s Class A common stock at an exercise price of $0.705 per share. Both shares and options shall vest upon the earliest to occur of the following: (1) one third upon the first anniversary of the effective date, one third upon the second anniversary of the effective date, and the remaining one third upon the third anniversary of the effective date; or (2) upon a change in control of the Company. The 58,394 shares were valued at approximately $41,000 and the 172,987 stock options valued at approximately $112,000. Both shares and options will be amortized over 3 years to September 1, 2020 unless the other vesting requirements are met sooner. During the three months and nine months ended March 31, 2018, the Company recorded approximately $13,000 and $30,000 of total stock-based compensation, respectively. The $13,000 of stock-based compensation expense for the three months ended March 31, 2018 included approximately $9,000 of stock option expense and $4,000 of stock awards. The $30,000 of stock-based compensation expense for the nine months ended March 31, 2018 included approximately $22,000 of stock option expense and $8,000 of stock awards.

On September 1, 2017, the Company agreed to grant to Anne Ponugoti, under the 2016 Plan, ten-year options to purchase 5,000 shares of the Company’s common stock at an exercise price of $0.705 per share, which shall vest upon the earliest to occur of the following: (1) one third upon the first anniversary of the effective date, one-third upon the second anniversary of the effective date, and the remaining one-third upon the third anniversary of the effective date; or (2) upon a change in control of the Company. The 5,000 stock options were valued at approximately $3,000 and will be amortized over 3 years to September 1, 2020 unless the other vesting requirements are met sooner. During the three months and nine months ended March 31, 2018, the Company recorded approximately $300 and $700 of stock option expense for this option grant.

On January 9, 2017, the Company and Ms. Ponugoti entered into an executive employment agreement as the Company’s Associate Director, Clinical Sciences, effective on February 1, 2017. Pursuant to the employment agreement, the Company issued 10,000 shares of restricted stock and options to purchase 30,000 shares of common stock under the 2016 Plan. During the three months and nine months ended March 31, 2018, the Company recorded approximately $3,000 and $9,000 of total stock-based compensation, respectively. The $3,000 of stock-based compensation expense for the three were months ended March 31, 2018 included approximately $2,000 of stock option expense and $1,000 of stock awards. The $10,000 of stock-based compensation expense for the nine months ended March 31, 2018 included approximately $7,000 of stock option expense and $3,000 of stock awards.

Purchase of Treasury Stock - cash paid to Federal and State Taxing Authorities arising from the withholding of common shares from officers’ vested restricted stock grant issuance and issuance of Treasury Stock and the reversal of outstanding stock subscription receivable

On September 1, 2017, 19,465 shares of the Company’s restricted stock vested to Ms. Harness according to Ms. Harness’s employment agreement. The total taxable compensation to Ms. Harness for the 19,465 vested shares was $14,000, which is priced at the closing stock price on September 1, 2017 at $0.705 a share.

The Company issued 12,409 common shares (net share issuance amount), which is approximately 64% of the total vested common share amount of 19,465 common shares due to be issued to Ms. Harness. The remaining 7,056 shares of common stock were withheld from Ms. Harness for the payment of payroll taxes to the Federal and State taxing authorities and these shares withheld are being reported by the Company as treasury stock, at cost, on the Company’s accompanying balance sheets.

On December 22, 2017, 533,334 shares of the Company’s restricted stock vested to Dr. Bertolino according to Dr. Bertolino’s employment agreement. The total taxable compensation to Dr. Bertolino for the 533,334 vested shares was $373,334, which is priced at the closing stock price on December 21, 2017 at $0.7 a share.

The Company issued 295,286 common shares (net share issuance amount), which is approximately 55% of the total vested common share amount of 533,334 common shares due to be issued to Dr. Bertolino. The remaining 238,048 shares of common stock were withheld from Dr. Bertolino for the payment of payroll taxes to the Federal and State taxing authorities and these shares withheld are being reported by the Company as treasury stock, at cost, on the Company’s accompanying balance sheets.

In addition, the Company reversed an outstanding stock subscription receivable of $26,000 for 60,000 shares of common stock and recorded this amount as the cost of treasury stock.

On February 1, 2018, 3,333 shares of the Company’s restricted stock vested to Ms. Anne Ponugoti according to Ms. Ponugoti’s employment agreement. The total taxable compensation to Ms. Ponugoti for the 3,333 vested shares was $2,433, which is priced at the closing stock price on January 31, 2018 at $0.73 a share. The Company issued 2,645 common shares (net share issuance amount), which is approximately 79% of the total vested common share amount of 3,333 common shares due to be issued to Ms. Ponugoti. The remaining 688 shares of common stock were withheld from Ms. Ponugoti for the payment of payroll taxes to the Federal and State taxing authorities.

On February 5, 2018, the Board of Directors approved the retirement of 567,872 shares of its common stock in treasury, which shares are issued but are not outstanding. These shares included the 688 shares withheld from Ms. Ponugoti, as a result, all treasury shares of the Company were retired.

There were 0 shares and 262,080 shares of treasury stock outstanding at March 31, 2018 and June 30, 2017, respectively, purchased at a total cumulative cost of $0 and $220,000 at March 31, 2018 and June 30, 2017, respectively.

Restricted Stock Awards Outstanding

The following summarizes our restricted stock activity for our restricted stock issuances:

				Weighted
				Average
				Grant
	Number of			Date Fair
	Shares			Value
Total awards outstanding at June 30, 2017		601,728		$	1.39
Total shares granted		1,125,061			0.71
Total shares vested		(556,132	)		1.40
Total shares forfeited
Total unvested shares outstanding at March 31, 2018		1,170,657		$	0.73

Scheduled vesting for outstanding restricted stock awards at March 31, 2018 is as follows:

	Year Ending June 30,
	2018		2019		2020		2021		Total
Scheduled vesting		0		575,596		575,597		19,464		1,170,657

As of March 31, 2018, there was approximately $0.6 million of net unrecognized compensation cost related to unvested restricted stock-based compensation arrangements. This compensation is recognized on a straight-line basis resulting in approximately $0.4 million of compensation expected to be expensed over the next twelve months, and the total unrecognized stock-based compensation expense having a weighted average recognition period of 1.48 years.

For the nine months ended March 31, 2017

Issuances of Common Stock and Stock Options – Pursuant to New Employment Agreements

On June 27, 2016, the Company and Dr. Bertolino entered into an executive employment agreement as our President and Chief Medical Officer of the Company, effective on June 27, 2016 and the Company agreed to grant to Dr. Bertolino under the Company’s 2016 Equity Incentive Plan (i) 1,066,667 shares of restricted stock and (ii) a ten-year option to purchase 617,839 shares of the Company’s Class A common stock at an exercise price of $1.39 per share. Both shares and options shall vest upon the earliest to occur of the following: (1) 50% upon the first anniversary of the effective date, and the remaining 50% upon the second anniversary of the effective date (2) completion of both a Phase 2b psoriasis study and a Phase 2 oral mucositis study; (3) the Company’s common stock closes above $3.00 per share (as may be adjusted for any stock splits or similar actions); (4) the commencement of trading of the Company’s common stock on a national securities exchange (e.g. Nasdaq or the NYSE); or (5) upon a Change in Control of the Company (as defined in the employment agreement). The 1,066,667 shares were valued at approximately $1.5 million, which will be amortized over two years to June 27, 2018. The 617,839 stock options valued at approximately $800,000 and will be exercisable for 10 years at an exercise price of $1.39 per share. During the three months and nine months ended March 31, 2018, the Company recorded approximately $0 and $1,134,000 of total stock-based compensation, respectively. There was no stock-based compensation expense for the three months ended March 31, 2018 for it was fully expensed. The $1,134,000 of stock-based compensation expense for the nine months ended March 31, 2018 included approximately $396,000 of stock option expense and $738,000 of stock awards.

In December, 2017 and October, 2017, respectively, the Company was able to conclude both the Phase 2b psoriasis study and a Phase 2 oral mucositis study; therefore the remaining 50% of the shares and options vested to Dr. Bertolino, and all remaining shares and options granted on June 27, 2016 were fully amortized and expensed in December, 2017.

On July 18, 2016, the Company issued 7,500 stock options to purchase shares of the Company’s common stock to a consultant for services rendered, exercisable for 3 years at $1.38 per share of common stock. The value of these 7,500 options was approximately $4,000. During the three months ended September 30, 2016, the Company recorded approximately $4,000 of stock option expense for this option grant.

On September 1, 2016, the Company and Ms. Harness entered into an executive employment agreement as the Company’s VP, Clinical Sciences and Portfolio Management, effective on September 1, 2016. Commencing on September 1, 2016, the Company agreed to pay Ms. Harness an annual salary of $250,000. In addition, the Company agreed to grant to Ms. Harness, under the 2016 Plan (i) 58,394 shares of restricted stock, which shall vest upon the earliest to occur of the following: (1) one third upon the first anniversary of the effective date, one-third upon the second anniversary of the effective date, and the remaining one-third upon the third anniversary of the effective date; or (2) upon a Change in Control (as defined in the employment agreement) of the Company, and (ii) ten-year options to purchase 172,987 shares of the Company’s common stock were also granted at an exercise price of $1.37 per share, which shall vest upon the earliest to occur of the following: (1) one-third upon the first anniversary of the effective date, and the remaining balance vesting monthly in equal portions over the following 24 months; and (2) upon a Change in Control (as defined in the employment agreement) of the Company. The 58,394 shares were valued at approximately $80,000, which will be amortized over three years to September 1, 2019. The 172,987 stock options were valued at approximately $220,000 and will be exercisable for 10 years at an exercise price of $1.37 per share. They will be amortized over 3 years to September 1, 2019. During the three months and nine months ended March 31, 2018, the Company recorded approximately $25,000 and $75,000 of total stock-based compensation, respectively. The $25,000 of stock-based compensation expense for the three months ended March 31, 2018 included approximately $18,000 of stock option expense and $7,000 of stock awards. The $75,000 of stock-based compensation expense for the nine months ended March 31, 2018 included approximately $54,000 of stock option expense and $21,000 of stock awards.

Exercise of options

During the three months and nine months ended March 31, 2018 and 2017, there were no stock options exercised.

XML

Equity Transactions

9 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Note 11 - Equity Transactions

$30 million Class A Common Stock Purchase Agreement with Aspire Capital

On September 6, 2017, the Company entered into a common stock purchase agreement with Aspire Capital, which replaced the prior 2015 $30 million Aspire Capital stock purchase agreement and provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company’s common stock over the 36-month term of the Stock Purchase Agreement. The Company issued 300,000 shares of its Class A common stock to Aspire Capital as a commitment fee. The commitment fee of approximately $215,000 is amortized pro-rata as the funding is received. The amortized amount of $41,000 was recorded to additional paid-in capital for the nine months ended March 31, 2018. The unamortized portion is carried on the balance sheet as deferred offering costs and was $173,000 at March 31, 2018. The Company registered the sale of all shares that Aspire Capital will purchase under this common stock purchase agreement. To the extent Aspire Capital purchases shares under this Purchase Agreement and subsequently sells those shares purchased, the other holders of shares of our Class A common stock may experience dilution, which may be substantial. In addition, the sale of a substantial number of shares of our Class A common stock by Aspire Capital, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we might otherwise wish to effect sales.

During the period from September 6, 2017 to March 31, 2018, the Company generated proceeds of approximately $5.7 million under the new 2017 agreement with Aspire Capital from the sale of approximately 8.7 million shares of its common stock. As of March 31, 2018, the available balance under the new equity line agreement was approximately $24.3 million.

On March 30, 2015, the Company entered into its prior common stock purchase agreement with Aspire Capital, which provided that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $30.0 million of the Company’s common stock over the 36-month term of the Purchase Agreement. In consideration for entering into this stock purchase agreement, the Company issued to Aspire Capital 160,000 shares of its Class A common stock as a commitment fee. The commitment fee of approximately $499,000 was amortized as the funding was received. The unamortized portion of deferred offering costs from this stock purchase agreement of $227,000 was recorded to additional paid-in capital in September, 2017, since the Company entered into a new $30 million common stock purchase agreement with Aspire Capital, to replace this prior $30 million 2015 Aspire Capital agreement, on September 6, 2017. During the period from July 1, 2017 to September 5, 2017, the Company generated proceeds of approximately $2.1 million under this 2015 agreement with Aspire Capital, from the sale of approximately 2.6 million shares of its common stock.

XML

Subsequent Events

9 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Note 12 - Subsequent Events

Equity Transactions

From April 1, 2018 to May 9, 2018, the Company has generated additional proceeds of approximately $2.0 million under the Common Stock Purchase Agreement with Aspire Capital from the sale of approximately 8.0 million shares of its common stock.

XML

Significant Accounting Policies and Recent Accounting Pronouncements (Policies)

9 Months Ended

Mar. 31, 2018

Significant Accounting Policies And Recent Accounting Pronouncements Policies

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research accruals, recoverability of long-lived assets, measurement of stock-based compensation, and the periods of performance under collaborative research and development agreements. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.

Net Loss Per Share

Basic and diluted loss per share is computed based on the weighted-average common shares and common share equivalents outstanding during the period. Common share equivalents consist of stock options, convertible notes payable underlying shares and unvested restricted stock. Common share equivalents of 47 million and 46 million shares of common stock were excluded from the computation of diluted loss per share for the nine months ended March 31, 2018 and 2017, respectively, because we incurred net losses for the nine months ended March 31, 2018 and 2017, and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive and are therefore not included in the calculations.

Treasury Stock

The Company accounts for treasury stock using the cost method. There were 0 shares and 262,080 shares of treasury stock outstanding, purchased at a total cumulative cost of $0 and $220,000 at March 31, 2018 and June 30, 2017, respectively (see Note 10).

Treasury stock, representing shares of the Company’s common stock that have been acquired for payroll tax withholding on vested stock grants, is recorded at its acquisition cost and these shares are not considered outstanding.

Accounting for Stock Based Compensation

The stock-based compensation expense incurred by the Company for employees and directors in connection with its stock option plan is based on the employee model of ASC 718, and the fair market value of the options is measured at the grant date. Under ASC 718, an employee is defined as “An individual over whom the grantor of a share-based compensation award exercises or has the right to exercise sufficient control to establish an employer-employee relationship based on common law as illustrated in case law and currently under U.S. tax regulations”. Our consultants do not meet the employer-employee relationship as defined by the IRS and therefore are accounted for under ASC 505-50.

ASC 505-50-30-11 further provides that an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date:

i.	The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and
ii.	The date at which the counterparty’s performance is complete.

We have elected to use the Black-Scholes-Merton pricing model to determine the fair value of stock options on the dates of grant. Restricted stock is measured based on the fair market values of the underlying stock on the dates of grant. We recognize stock-based compensation using the straight-line vesting method over the requisite service period of the equity awards.

The components of stock-based compensation expense included in the Company’s Condensed Statements of Operations for the three months and nine months ended March 31, 2018 and 2017 are as follows (rounded to nearest thousand):

	Three months ended March 31				Nine months ended March 31
	2018		2017		2018		2017
Research and development expenses
Professional fees	$	80,000	$	5,000	$	80,000	$	55,000
Employees’ bonus		41,000		48,000		115,000		110,000
Officers’ bonus		144,000		283,000		1,470,000		861,000
Total stock-based compensation expense	$	265,000	$	336,000	$	1,665,000	$	1,026,000

Recent Adopted Accounting Pronouncements

Stock Compensation - In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which simplified the income tax consequences, accounting for forfeitures and classification on the Statement of Cash Flows with (i) excess tax benefits being classified as cash inflows provided by operating activities, and (ii) cash paid to taxing authorities arising from the withholding of shares from employees being classified as cash outflows used in financing activities. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016, with early adoption permitted. This new pronouncement was adopted on July 1, 2016 and did not have a material effect on the Company’s financial position or results of operations, but had an effect of the classification of cash paid to taxing authorities arising from the withholding of shares from employees (treasury stock), classified as cash outflows used in financing activities.

In June 2014, the FASB issued ASU 2014-12, “Compensation—Stock Compensation.” The amendments in this ASU apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target can be achieved after the requisite service period. This ASU is the final version of Proposed ASU EITF-13D, “Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period,” which has been deleted. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. As indicated in the definition of vest, the stated vesting period (which includes the period in which the performance target could be achieved) may differ from the requisite service period. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The implementation of this standard did not have a material impact on the Company’s accompanying condensed financial statements.

Recently Issued Accounting Guidance

In May 2014, the FASB issued authoritative guidance that defines how companies should report revenues from contracts with customers. The standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It provides companies with a five-step, principles-based model to use in accounting for revenue and supersedes current revenue recognition requirements, including most industry-specific and transaction-specific revenue guidance. In August 2015, the FASB deferred the effective date of the new revenue standard by one year. As a result, the new standard would not be effective for the Company until 2019. In addition, the FASB is allowing companies to early adopt this guidance for non-public entities beginning in fiscal year 2017. The guidance permits an entity to apply the standard retrospectively to all prior periods presented, with certain practical expedients, or apply the requirements in the year of adoption, through a cumulative adjustment. The Company will apply this new guidance when it becomes effective and has not yet selected a transition method. The Company, due to not having any revenue currently and in the foreseeable future, has concluded that the impact of the adoption of this accounting standard on its financial statements will not be material.

In February 2016, FASB issued ASU No. 2016-02, “Leases (Topic 842)”. The guidance requires that a lessee recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right of use asset representing its right to use the underlying asset for the lease term. The guidance requires the following for finance leases: the right-of-use asset and a lease liability will be initially measured at the present value of the lease payments, in the statement of financial position; interest on the lease liability will be recognized separately from amortization of the right-of-use asset in the statement of comprehensive income; and repayments of the principal portion of the lease liability will be classified within financing activities and payments of interest on the lease liability and variable lease payments within operating activities in the statement of cash flows. The guidance requires the following for operating leases: the right-of-use asset and a lease liability will be initially measured at the present value of the lease payments, in the statement of financial position; a single lease cost will be recognized, calculated so that the cost of the lease is allocated over the lease term on a generally straight-line basis; and all cash payments will be classified within operating activities in the statement of cash flows. Under Topic 842 the accounting applied by a lessor is largely unchanged from that applied under previous U.S. GAAP. The amendments in Topic 842 are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Management has determined that based on current accounting and lease contract information the adoption of ASU No. 2016-02 is not expected to have a significant impact on the Company’s financial position, results of operations and disclosures. However, management is continually evaluating the future impact of ASU No. 2016-02 based on changes in the Company’s financial statements through the period of adoption.

Intangibles, Goodwill and Other —In January 2017, the FASB issued ASU No. 2017-04, “Intangibles – Goodwill and Other (Topic 350) – Simplifying the Test for Goodwill Impairment” (“ASU No. 2017-04”). To simplify the subsequent measurement of goodwill, ASU No. 2017-04 eliminates Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, ASU No. 2017-04 requires an entity to perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. ASU No. 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore, the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU No. 2017-04 is effective for fiscal years beginning after December 15, 2019. The Company will adopt ASU No. 2017-04 commencing in the first quarter of fiscal 2021. The Company does not believe this standard will have a material impact on its financial statements or the related footnote disclosures.

Statement of Cash Flows — In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force)” (“ASU No. 2016-15”). ASU No. 2016-15 clarifies how certain cash receipts and payments should be presented in the statement of cash flows. ASU No. 2016-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company will adopt ASU No. 2016-15 commencing in the first quarter of fiscal 2019. The Company does not believe this standard will have a material impact on its financial statements or the related footnote disclosures.

XML

Significant Accounting Policies and Recent Accounting Pronouncements (Tables)

9 Months Ended

Mar. 31, 2018

Significant Accounting Policies And Recent Accounting Pronouncements Tables

Schedule of components of stock based compensation related to stock options recognized in the company's statement of operations

	Three months ended March 31				Nine months ended March 31
	2018		2017		2018		2017
Research and development expenses
Professional fees	$	80,000	$	5,000	$	80,000	$	55,000
Employees’ bonus		41,000		48,000		115,000		110,000
Officers’ bonus		144,000		283,000		1,470,000		861,000
Total stock-based compensation expense	$	265,000	$	336,000	$	1,665,000	$	1,026,000

XML

Patents, net (Tables)

9 Months Ended

Mar. 31, 2018

Patents Net Tables

Schedule of patents

	Useful life	March 31,			June 30,
	(years)	2018			2017
Purchased Patent Rights – Brilacidin, and related compounds	14	$	4,082,000		$	4,082,000
Purchased Patent Rights – Anti-microbial – surfactants and related compounds	12		144,000			144,000
Patents – Kevetrin and related compounds	17		1,417,000			1,308,000
			5,643,000			5,534,000
Less: Accumulated amortization for Brilacidin, Anti-microbial- surfactants and related compounds			(1,386,000	)		(1,158,000	)
Accumulated amortization for Patents –Kevetrin and related compounds			(225,000	)		(164,000	)
		$	4,032,000		$	4,212,000

XML

Accrued Expenses (Tables)

9 Months Ended

Mar. 31, 2018

Accrued Expenses Tables

Schedule of accrued expenses

	March 31,		June 30,
	2018		2017
Accrued research and development consulting fees	$	281,000	$	673,000
Accrued rent (Note 8) – related parties		13,000		21,000
Accrued interest – (Note 9) related parties		12,000		17,000
Total	$	306,000	$	711,000

XML

Accrued Salaries and Payroll Taxes - Related Parties And Other (Tables)

9 Months Ended

Mar. 31, 2018

Accrued Salaries And Payroll Taxes - Related Parties And Other Tables

Schedule of accrued salaries and payroll taxes

	March 31,		June 30,
	2018		2017
Accrued salaries - related parties	$	2,823,000	$	2,823,000
Accrued payroll taxes - related parties		130,000		130,000
Accrued employee bonuses		-		86,000
Withholding tax - payroll		64,000		105,000
Total	$	3,017,000	$	3,144,000

XML

Commitments and Contingencies (Tables)

9 Months Ended

Mar. 31, 2018

Commitments And Contingencies Tables

Future minimum lease payments required under the non-cancelable operating lease

Year ending June 30,
2018	$	54,000
2019		54,000
Total minimum payments	$	108,000

XML

Equity Incentive Plans, Stock-Based Compensation and Warrants (Tables)

9 Months Ended

Mar. 31, 2018

Equity Incentive Plans Stock-based Compensation And Warrants Tables

Schedule of stock option activity

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding at June 30, 2017		40,655,245		$	0.22		3.61	$	31,662,730
Granted		1,070,826			0.75		8.14
Forfeited/expired		(277,924	)		2.44
Outstanding at March 31, 2018		41,448,147			0.22		3.01	$	14,819,300
Exercisable at March 31, 2018		40,452,299			0.21		2.87	$	14,819,300

Valuation assumptions for stock options/warrants and SARs

	Nine months ended
	March 31,
	2018	2017
Expected term (in years)	5 - 10	3 - 10
Expected stock price volatility	52.80% to 106.01%	57.63% to 111.62%
Risk-free interest rate	2.15% to 2.56%	0.71% to 2.49%
Expected dividend yield	0	0

Schedule of Restricted Stock Award Activity

				Weighted
				Average
				Grant
	Number of			Date Fair
	Shares			Value
Total awards outstanding at June 30, 2017		601,728		$	1.39
Total shares granted		1,125,061			0.71
Total shares vested		(556,132	)		1.40
Total shares forfeited
Total unvested shares outstanding at March 31, 2018		1,170,657		$	0.73

Schedule of vesting outstanding restricted stock

	Year Ending June 30,
	2018		2019		2020		2021		Total
Scheduled vesting		0		575,596		575,597		19,464		1,170,657

XML

Basis of Presentation and Nature of Operations (Details Narrative)	9 Months Ended
	Mar. 31, 2018
Basis Of Presentation And Nature Of Operations Details Narrative
State of incorporation	Nevada
Date of incorporation	Aug. 01, 2005

XML

Going Concern and Liquidity (Details Narrative) - USD ($)	2 Months Ended	3 Months Ended		7 Months Ended	9 Months Ended
	Sep. 05, 2017	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2018	Mar. 31, 2017	Sep. 06, 2017	Jun. 30, 2017	Jun. 30, 2016
Accumulated deficit		$ (81,054,000)		$ (81,054,000)	$ (81,054,000)			$ (69,553,000)
Cash and cash equivalents		1,336,000	$ 5,613,000	1,336,000	1,336,000	$ 5,613,000		4,141,000	$ 6,310,000
Net cash used in operating activities					(10,362,000)	(7,949,000)
Net loss		(2,449,000)	(3,903,000)		(11,501,000)	(10,289,000)
Working capital (deficit)		(8,000,000)	$ (6,100,000)	(8,000,000)	(8,000,000)	$ (6,100,000)
Current liabilities		9,467,000		9,467,000	9,467,000			$ 10,576,000
Related parties liabilities		6,500,000		6,500,000	6,500,000
Total budgeted expenditures					(12,200,000)
Total available balance		$ 24,300,000		$ 24,300,000	$ 24,300,000
Aspire Capital Fund LLC [Member] | 2017 agreement [Member]
Common stock purchase agreement shares sold				8,700,000
Additional proceeds from common stock purchase agreement				$ 5,700,000
Aspire Capital Fund LLC [Member] | April 2015 agreement [Member]
Common stock purchase agreement shares sold	2,600,000
Additional proceeds from common stock purchase agreement	$ 2,100,000
Aspire Capital Fund LLC [Member] | Stock purchase agreement [Member]
Shares reserved for future issuance under agreement, Value							$ 30,000,000
Share reserved for future issuance, Value cancelled							$ 30,000,000

XML

Significant Accounting Policies and Recent Accounting Pronouncements (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Research and development expenses:
Professional fees	$ 195,000	$ 201,000	$ 525,000	$ 562,000
Total stock-based compensation expense			400,000
Research and Development Expense [Member]
Research and development expenses:
Professional fees	80,000	5,000	80,000	55,000
Employees' bonus	41,000	48,000	115,000	110,000
Officers' bonus	144,000	283,000	1,470,000	861,000
Total stock-based compensation expense	$ 265,000	$ 336,000	$ 1,665,000	$ 1,026,000

XML

Significant Accounting Policies and Recent Accounting Pronouncements (Detail Narrative) - USD ($)	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2017
Significant Accounting Policies And Recent Accounting Pronouncements Detail Narrative
Treasury Stock value	0		262,080
Purchase of treasury stock, value	$ 0		$ 220,000
Diluted earnings (loss) per share	47,000,000	46,000,000

XML

Patents, net (Details) - USD ($)	9 Months Ended
	Mar. 31, 2018	Jun. 30, 2017
Purchased Patent Rights	$ 5,643,000	$ 5,534,000
Patent costs - net	$ 4,032,000	4,212,000
Patents [Member]
Useful life	14 years
Purchased Patent Rights	$ 4,082,000	4,082,000
Accumulated amortization	$ (1,386,000)	(1,158,000)
Patents Two [Member]
Useful life	12 years
Purchased Patent Rights	$ 144,000	144,000
Patents Three [Member]
Useful life	17 years
Purchased Patent Rights	$ 1,417,000	1,308,000
Accumulated amortization	$ (225,000)	$ (164,000)

XML

Patents, net (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Amortization expense	$ 96,000	$ 95,000	$ 289,000	$ 277,000
Minimum and Intangible Assets - Patent (Member)
Estimated remaining useful lives of the assets			12 years
Amortization period			7 years 5 months 5 days
Maxiimum and Intangible Assets - Patent (Member)
Estimated remaining useful lives of the assets			17 years
Amortization period			16 years 9 months
Year 2026 [Member]
Estimated annual amortization expense			$ 374,000
Year 2019 - 2025 [Member]
Estimated annual amortization expense			383,000
Year 2018 [Member]
Estimated annual amortization expense			96,000
Year 2027 [Member]
Estimated annual amortization expense			371,000
Year 2028 [Member]
Estimated annual amortization expense			134,000
Year 2029 - 2032 [Member]
Estimated annual amortization expense			80,000
Year 2033 [Member]
Estimated annual amortization expense			41,000
Year 2034 [Member]
Estimated annual amortization expense			10,000
Year 2035 [Member]
Estimated annual amortization expense			$ 2,000

XML

Accrued Expenses (Details) - USD ($)	Mar. 31, 2018	Jun. 30, 2017
Accrued Expenses Details
Accrued research and development consulting fees	$ 281,000	$ 673,000
Accrued rent (Note 8) - related parties	13,000	21,000
Accrued interest (Note 9) - related parties	12,000	17,000
Total	$ 306,000	$ 711,000

XML

Accrued Salaries and Payroll Taxes - Related Parties And Other (Details) - USD ($)	Mar. 31, 2018	Jun. 30, 2017
Accrued Salaries And Payroll Taxes - Related Parties And Other Details
Accrued salaries - related parties	$ 2,823,000	$ 2,823,000
Accrued payroll taxes - related parties	130,000	130,000
Accrued salaries - employees		86,000
Withholding tax - payroll	64,000	105,000
Total	$ 3,017,000	$ 3,144,000

XML

Commitments and Contingencies (Details)	Mar. 31, 2018 USD ($)
Year ending June 30,
2018	$ 54,000
2019	54,000
Total minimum payments	$ 108,000

XML

Commitments and Contingencies (Details Narrative)	3 Months Ended		9 Months Ended
	Mar. 31, 2018 USD ($) ft²	Mar. 31, 2017 USD ($)	Mar. 31, 2018 USD ($) ft²	Mar. 31, 2017 USD ($)
Operating leases, rental expense	$ 53,000	$ 52,000	$ 157,000	$ 153,000
Lease term			5 years
Lease expiry date			Sep. 30, 2018
Rent expense (monthly)			$ 18,000
Lease commencement date			Oct. 01, 2013
Total contractual commitments	$ 1,000,000		$ 1,000,000
Sublease [Member]
Rental income			$ 900
Area used by officers | ft²	200		200

XML

Related Party Transactions (Details Narrative)	3 Months Ended		9 Months Ended
	Mar. 31, 2018 USD ($) ft²	Mar. 31, 2017 USD ($)	Mar. 31, 2018 USD ($) ft²	Mar. 31, 2017 USD ($)	Jun. 30, 2017 USD ($)
Lease term			5 years
Rent expense (monthly)			$ 18,000
Lease commencement date			Oct. 01, 2013
Lease expiry date			Sep. 30, 2018
Sublease [Member]
Rental income			$ 900
Area used by officers | ft²	200		200
Clinical Studies [Member]
Accrued research and development expenses	$ 1,486,000		$ 1,486,000		$ 1,486,000
Innovative Medical Research Inc [Member]
Accrued rent expenses	3,000	$ 3,000	9,000	$ 9,000
Kard Scientific [Member]
Rent payable	$ 13,000		$ 13,000		$ 21,000

XML

Convertible Note Payable - Related Party (Details Narrative) - USD ($)		12 Months Ended
	May 07, 2012	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2010	Mar. 31, 2018	Jun. 30, 2017	May 08, 2012	Mar. 31, 2012	Dec. 31, 2010	Oct. 01, 2009
Accrued interest - related parties					$ 12,000	$ 17,000
Principal balance of demand notes					$ 2,022,000	$ 2,022,000
Ehrlich Promissory Note C [Member]
Accrued interest - related parties									$ 97,000
Principal balance of demand notes							$ 2,248,000
Interest rate				9.00%
Common stock price per share				$ 0.50
Equity Incentive shares	2,000,000
Options exercisable, price per share	$ 0.51
Closing bid price per share	$ 0.46
Percentage of closing bid price	110.00%
Equity incentive options exercisable period	10 years
Mr. Ehrlich [Member]
Principal balance of demand notes		$ 2,022,000	$ 2,002,000
Additional loan amount		$ 20,000	$ 997,000	$ 973,000
Ehrlich Promissory Notes A and B [Member]
Interest rate										9.00%
Maximum [Member] | Ehrlich Promissory Note C [Member]
Interest rate								10.00%
Minimum [Member] | Ehrlich Promissory Note C [Member]
Interest rate								9.00%

XML

Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding (Details)	9 Months Ended
	Mar. 31, 2018 USD ($) $ / shares shares
Number of Outstanding, Beginning Balance | shares	601,728
Number of Outstanding, Ending Balance | shares	1,170,657
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 1.39
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 0.73
Stock Options [Member]
Number of Outstanding, Beginning Balance | shares	40,655,245
Granted | shares	1,070,826
Forfeited/expired | shares	(277,924)
Number of Outstanding, Ending Balance | shares	41,448,147
Number of Outstanding, Exercisable | shares	40,452,299
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.22
Granted | $ / shares	0.75
Forfeited/expired | $ / shares	2.44
Weighted Average Exercise Price, Ending Balance | $ / shares	0.22
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.21
Weighted average remaining contractual life (Years), Outstanding, Beginning Balance	3 years 7 months 10 days
Granted	8 years 1 month 20 days
Weighted average remaining contractual life (Years), Outstanding, Ending Balance	3 years 4 days
Weighted average remaining contractual life (Years), Exercisable	2 years 10 months 13 days
Aggregate intrinsic value, Beginning Balance | $	$ 31,662,730
Aggregate intrinsic value, Ending Balance | $	14,819,300
Aggregate intrinsic value, Exercisable | $	$ 14,819,300

XML

Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding (Details 1) - Stock Options [Member]	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Expected term (in years)	5 years	3 years
Expected stock price volatility	52.80%	57.63%
Risk-free interest rate	2.15%	0.71%
Expected dividend yield
Maximum [Member]
Expected term (in years)	10 years	10 years
Expected stock price volatility	106.01%	111.62%
Risk-free interest rate	2.56%	2.49%
Expected dividend yield

XML

Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding (Details 2)	9 Months Ended
	Mar. 31, 2018 $ / shares shares
Equity Incentive Plans Stock-based Compensation Exercise Of Options And Warrants Outstanding Details 2
Number of Outstanding, Beginning Balance | shares	601,728
Total shares granted | shares	1,125,061
Total shares vested | shares	(556,132)
Total shares forfeited | shares
Number of Outstanding, Ending Balance | shares	1,170,657
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 1.39
Total shares granted | $ / shares	0.71
Total shares vested | $ / shares	1.40
Total shares forfeited | $ / shares
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 0.73

XML

Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding (Details 3) - shares	9 Months Ended	12 Months Ended
	Mar. 31, 2018	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Scheduled vesting	1,170,657
Restricted Stock [Member]
Scheduled vesting		19,464	575,597	575,596	0

XML

Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding (Details Narrative) - USD ($)

3 Months Ended

9 Months Ended

Mar. 31, 2018

Mar. 31, 2017

Sep. 30, 2016

Mar. 31, 2018

Mar. 31, 2017

Dec. 31, 2017

Jun. 30, 2017

Jun. 30, 2016

Stock based compensation

$ 265,000

$ 336,000

$ 1,665,000

$ 1,026,000

Stock option expenses

677,000

Restricted stock awards

988,000

Cash

$ 1,336,000

$ 5,613,000

1,336,000

5,613,000

$ 4,141,000

$ 6,310,000

Proceeds from exercise of rights

Reversal of subscription receivable to treasury stock

$ 26,000

Shares issued

60,000

60,000

Treasury stock, shares outstanding

0

0

262,080

Treasury Stock

$ 0

$ 0

$ 220,000

Unrecognized compensation cost related to unvested restricted stock-based compensation

$ 600,000

$ 600,000

Compensation cost not yet recognized, period for recognition

1 year 5 months 23 days

Expected share based compensation expenses

$ 400,000

Common Class A

Common stock shares issued

147,091,427

147,091,427

135,536,501

Common stock per shares

$ 0.0001

$ 0.0001

$ 0.0001

Common stock value

$ 15,000

$ 15,000

$ 14,000

On June 30, 2016 [Member] | 2016 Equity Incentive Plan [Member]

Stock option vested, description

Up to 20,000,000 shares of the Company’s Class A common stock may be issued under the 2016 Plan (subject to adjustment as described in the 2016 Plan); provided that (1) no Outside Director (as defined in the 2016 Plan) may be granted awards covering more than 250,000 shares of common stock in any year and (2) no participant shall be granted, during any one year period, options to purchase common stock and stock appreciation rights with respect to more than 4,000,000 shares of common stock in the aggregate or any other awards with respect to more than 2,500,000 shares of common stock in the aggregate.

Board of Directors [Member] | On February 5, 2018 [Member]

Common stock shares withheld

688

Treasury Stock

$ 567,872

$ 567,872

Ms. Ponugoti [Member] | Stock Options [Member]

Restricted stock

10,000

10,000

Stock based compensation

$ 3,000

$ 9,000

Stock option expenses

2,000

7,000

Restricted stock awards

$ 1,000

3,000

Stock based compensation expense

$ 10,000

Ms. Ponugoti [Member] | On February 1, 2018 [Member] | Employment Agreement [Member]

Restricted stock

3,333

3,333

Common stock closing price

$ 0.73

$ 0.73

Stock based compensation

$ 2,433

Options vested or expected to vest

3,333

3,333

Stock issued, Shares

2,645

Common stock shares withheld

688

Vested percent

79.00%

Consultant One [Member] | On February 1, 2018 [Member] | Stock Options [Member]

Stock based compensation

$ 8,000

Stock issued, Shares

75,000

Consultant One [Member] | On February 10, 2017 [Member] | Stock Options [Member]

Stock based compensation

$ 72,000

Stock issued, Shares

75,000

Consultant [Member] | On February 1, 2018 [Member] | Stock Options [Member]

Stock based compensation

$ 8,000

Stock issued, Shares

75,000

Consultant [Member] | On February 10, 2017 [Member] | Stock Options [Member]

Stock based compensation

$ 72,000

Stock issued, Shares

50,000

Consultant [Member] | On July 18, 2016 [Member] | Stock Options [Member]

Exercisable period

3 years

Stock option expenses

$ 4,000

Stock options to purchase shares

7,500

Stock options to purchase shares, value

$ 4,000

Common stock per shares

$ 1.38

$ 1.38

Ms. Jane Harness [Member]

Exercisable period

3 years

Stock option vested, description

approximately 64% of the total vested common share amount of 19,465 common shares due to be issued to Ms. Harness.

Stock issued, Shares

12,409

Common stock shares withheld

7,056

Ms. Jane Harness [Member] | Stock Options [Member]

Exercisable period

3 years

Stock based compensation

$ 13,000

$ 30,000

Stock option expenses

9,000

22,000

Restricted stock awards

4,000

$ 8,000

Stock options to purchase shares

172,987

Stock options to purchase shares, value

$ 112,000

Ms. Jane Harness [Member] | On September 1, 2016 [Member]

Exercise price

$ 1.37

Exercisable period

10 years

Restricted stock

58,394

58,394

Stock option vested, description

i) 58,394 shares of restricted stock, which shall vest upon the earliest to occur of the following: (1) one third upon the first anniversary of the effective date, one-third upon the second anniversary of the effective date, and the remaining one-third upon the third anniversary of the effective date; or (2) upon a Change in Control (as defined in the employment agreement) of the Company

Stock based compensation

25,000

75,000

Stock option expenses

18,000

54,000

Restricted stock awards

$ 7,000

$ 21,000

Stock options to purchase shares

172,987

Stock options to purchase shares, value

$ 220,000

Stock option exercise price

$ 1.37

$ 1.37

Stock issued, Shares

58,394

Stock issued, Value

$ 80,000

Annual salary

$ 250,000

Ms. Jane Harness [Member] | On September 1, 2017 [Member]

Common stock closing price

$ 0.705

$ 0.705

Stock based compensation

$ 14,000

Options vested or expected to vest

19,465

19,465

Restricted stock forfeited

19,465

Ms. Jane Harness [Member] | On September 1, 2017 [Member] | Common Class A

Exercisable period

10 years

Restricted stock

58,394

58,394

Stock option vested, description

(1) one third upon the first anniversary of the effective date, one third upon the second anniversary of the effective date, and the remaining one third upon the third anniversary of the effective date

Stock options to purchase shares

172,987

Stock option exercise price

$ 0.705

$ 0.705

Stock issued, Shares

58,394

Stock issued, Value

$ 41,000

Dr. Arthur Bertolino [Member]

Exercisable period

2 years

Stock based compensation

$ 0

1,134,000

Stock option expenses

396,000

Restricted stock awards

$ 738,000

Dr. Arthur Bertolino [Member] | Stock Options [Member]

Exercisable period

2 years

Stock based compensation

144,000

$ 336,000

Stock option expenses

50,000

117,000

Restricted stock awards

$ 94,000

$ 219,000

Stock options to purchase shares

617,839

Stock options to purchase shares, value

$ 399,000

Dr. Arthur Bertolino [Member] | Stock option [Member]

Exercisable period

10 years

Stock options to purchase shares

617,839

Stock options to purchase shares, value

$ 800,000

Stock option exercise price

$ 1.39

Stock issued, Shares

1,066,667

Stock issued, Value

$ 1,500,000

Dr. Arthur Bertolino [Member] | On June 27, 2016 [Member] | Common Class A

Exercisable period

10 years

Restricted stock

1,066,667

1,066,667

Stock option vested, description

(1) 50% upon the first anniversary of the effective date, and the remaining 50% upon the second anniversary of the effective date

Common stock closing price

$ 3.00

$ 3.00

Stock option exercise price

$ 1.39

$ 1.39

Stock issued, Shares

617,839

Dr. Arthur Bertolino [Member] | On September 1, 2017 [Member] | Common Class A

Exercisable period

10 years

Restricted stock

1,066,667

1,066,667

Stock option vested, description

(1) 50% upon the first anniversary of the effective date, and the remaining 50% upon the second anniversary of the effective date

Common stock closing price

$ 3.00

$ 3.00

Stock options to purchase shares

617,839

Stock option exercise price

0.705

$ 0.705

Stock issued, Shares

1,066,667

Stock issued, Value

$ 752,000

Dr. Bertolino [Member]

Stock option vested, description

approximately 55% of the total vested common share amount of 533,334 common shares due to be issued to Dr. Arthur P. Bertolino

Stock issued, Shares

295,286

Common stock shares withheld

238,048

Dr. Bertolino [Member] | On December 22, 2017 [Member]

Common stock closing price

$ 0.7

$ 0.7

Stock based compensation

$ 373,334

Options vested or expected to vest

533,334

533,334

Restricted stock forfeited

533,334

Anne Ponugoti [Member] | Stock Options [Member]

Exercisable period

3 years

Restricted stock

5,000

5,000

Stock option vested, description

(1) one third upon the first anniversary of the effective date, one-third upon the second anniversary of the effective date, and the remaining one-third upon the third anniversary of the effective date

Stock option expenses

$ 300

$ 700

Stock options to purchase shares

5,000

Stock options to purchase shares, value

$ 3,000

Stock option exercise price

$ 0.705

$ 0.705

XML

Equity Transactions (Details Narrative) - USD ($)		1 Months Ended	2 Months Ended	7 Months Ended	9 Months Ended
	Sep. 06, 2017	Mar. 30, 2015	Sep. 05, 2017	Mar. 31, 2018	Mar. 31, 2018	Dec. 31, 2017	Jun. 30, 2017
Deferred offering costs				$ 173,000	$ 173,000		$ 227,000
Total available balance				24,300,000	24,300,000
Common Class A | 30 Million Common Stock Purchase Agreement [Member] | Aspire Capital Fund LLC [Member]
Term of the purchase agreement	36 months	36 months
Deferred offering costs				$ 173,000	173,000
Common stock shares issued	300,000	160,000
Common stock shares sold			2,600,000	8,700,000
Proceeds from issuance of common stock			$ 2,100,000	$ 5,700,000
Value of common stock shares issuable under agreement	$ 30,000,000	$ 30,000,000
Amortization of commitment fee, Amount amortized	$ 215,000	$ 499,000
Amortization recorded to additional paid in capital					41,000
Total available balance				$ 24,300,000	$ 24,300,000
Common Class A | New 30 Million Common Stock Purchase Agreement [Member] | Aspire Capital Fund LLC [Member]
Deferred offering costs						$ 227,000

XML

Subsequent Events (Details Narrative) - Subsequent Event [Member] - Aspire Capital Fund LLC [Member] - Equity Transactions [Member]	1 Months Ended
	May 09, 2018 USD ($) shares
Common stock shares sold | shares	8,000,000
Common stock shares sold, value | $	$ 2,000,000